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ABSTRACT 
 
Numerous marine-derived pyrrole 2-aminoimidazole alkaloids (P-2-AIs), 
including the highly potent antitumor natural product agelastatin A, are presumed to be 
derived from the simple precursor oroidin and related stuctures.  The molecular 
complexity of P-2AIs, significant biological activities, as well as the interesting 
biosynthetic routes proposed for their origin has made this family of alkaloids the subject 
of numerous synthetic investigations.   
Herein, a bioinspired total synthesis of agelastatin A is described premised on the 
isolation of two other P-2AIs, keramadine and nagelamide J. Two biosynthetically 
relevant cyclizations rapidly convert a linear precursor, resembling an oxidized 
keramadine, to agelastatin A.  A facile and highly diastereoselective C-ring formation 
via a 5-exo-trig cyclization or a Nazarov 4!-electrocyclization, proceeding through a 
deep-red colored N-acyliminium intermediate, constructs the three contiguous 
stereocenters of the cyclopentane core found in the agelastatins and nagelamide J.  A 
possible templating effect was discovered in a silica gel-assisted reaction that enables the 
final B-ring closure.  The described synthesis provided access to various agelastatin A 
derivatives leading to a bioactive biotin probe that is proving to be useful for cellular 
target identification.   
In an effort toward understanding the biosynthesis of P-2-AIs, a synthesis of 15N-
oroidin labeled oroidin was developed and pulse labeling and analysis by 1D 1H-15N 
HSQC NMR and FTMS experiments was validated as a direct method for measurement 
  iii 
of 15N incorporation into P2-AIs.  Studies toward the synthesis of a 15N-keramadine 
analog, which will be used to investigate the biosynthetic origin of agelastatin A, are 
also described.   
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CHAPTER I 
INTRODUCTION 
 
1.1 The Pyrrole-2-Aminoimidazole (P-2-AI) Alkaloids 
Nitrogen-rich alkaloids containing multiple heterocyclic motifs rank high among 
the most challenging targets in synthetic organic chemistry. One such example is the 
ever growing family of pyrrole-2-aminoimidazole (P-2-AI) alkaloids (Figure 1.1).1 Their 
structural complexity, compact stereochemical content, high nitrogen to carbon ratio, 
and widely varied biological activities have gained significant attention from a number 
of scientists from different fields worldwide. The simplest members of this family, 
oroidin 1.1 and its congeners hymenidine 1.2 and clathrodin 1.3, are proposed to be the 
key biosynthetic precursor of more complex members via diverse sequences of 
cyclization and dimerization.  To date, the Romo group has completed the 
enantioselective total syntheses of monomeric P-2-AI alkaloids, (+)-
dibromophakellstatin 1.52 and (+)-monobromophakellin 1.73.  Our ongoing unified 
synthetic strategy towards dimeric P-2-AI alkaloids, palau’amine 1.11 and the 
axinellamines 1.10, has revealed fascinating chemistry that plausibly mimics Nature’s 
elegant assembly of these metabolites through its complex machinery. While more than 
one hundred and fifty members isolated and characterized, many new congeners still 
continue to be detected aside from identification of new sources of known metabolites.  
Although biosynthetic evidence are scarce, successful implementation of synthetic 
strategies premised on speculative biosynthetic proposals1 have provided indirect 
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evidence of feasibility of biosynthetic pathways.  Among P-2-AIs, agelastatin A 1.8, is 
arguably the most popular within the synthetic community not only because of the 
challenge imposed by its highly compact structure but also due to the fact that it is 
arguably the most bioactive P-2-AI reported to date. 
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Figure 1.1 The pyrrole-2-aminoimidazole (P-2-AI) alkaloids 
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1.2 Previous Total Syntheses of Agelastatin A 
To date, a number of research groups worldwide have disclosed their own 
approaches to the total synthesis of agelastatin A.4  A variety of strategies have been 
employed to construct the unusual 5-6-5-5 tetracyclic ring system of the agalestatins.   
With all stereocenters in the molecule found decorating the cyclopentane C-ring, a 
common theme in most synthetic strategies is the construction of this ring with one or 
two of its stereocenters followed by substrate-controlled installation of the remaining 
stereocenters.  The most notable syntheses are revisited herein focusing on key strategies 
used that enabled synthesis completion. 
1.2.1 Weinreb’s Racemic Synthesis of Agelastatin A 
The Weinreb group has set the bar in this endeavor with their first total synthesis 
of racemic agelastatin A.4a,4b Their synthesis utilized several pericyclic reactions to 
construct the functionalized C-ring, starting off with a Hetero-Diels-Alder 4+2 
cyloaddition between diene 1.14 and dienophile 1.15 to give bicycle 1.16, which was 
immediately treated with phenyl magnesium bromide to produce allylic sulfoxide 1.17 
(Scheme 1.1).  With HMPT in methanol at elevated temperature, sulfoxide 1.17 
underwent a [2,3]-sigmatropic rearrangement with the intermediacy of sulfenate ester 
1.18, which spontaneously cyclizes to afford cyclopentene-fused oxazolidinone 1.20.  
Application of a Sharpless/Kresze allylic amination using 1.19 with refluxing toluene 
produced allylic sulfonamide 1.22 as a single regio- and stereoisomer.  This 
transformation presumably occurs via an ene reaction that generates 1.21 followed by a 
[2,3]-sigmatropic rearrangement to give 1.22.  After deprotection steps, acylation with 2-
   
 4 
trimethylsilyl pyrrole acyl chloride, hydrolysis of cyclic carbamate, and pyridinium 
dichromate oxidation, 1.22 was converted to enone 1.23.  Treatment of 1.23 with CsCO3 
provided the piperazinone B-ring 1.24.  It is noteworthy that this aza-Michael cyclization 
strategy developed by the Weinreb group has been utilized by other subsequent efforts 
toward agelastatins. 
 
Scheme 1.1 
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1.2.2 Feldman’s Synthesis of (–)-Agelastatins A and B 
The Feldman group accomplished the first enantioselective syntheses of both (–)-
agelastatins A and B in 2002.4c,4d  Alkynyliodonium  salt 1.26 was prepared from chiral 
epoxide 1.25 (Scheme 1.2).  Nucleophilic treatment of 1.26 with p-toluenesulfinate salt 
(TsNa) resulted in alkylidene-carbene 1.27, which underwent a substrate-controlled 
diastereoselective C-H insertion giving cyclopentene 1.28.  This step closed the C-ring 
with one stereocenter in place.  Another stereochemical setting step utilized in their 
approach is a convex face aza-Michael addition of ortho-nitrobenzylamine to vinyl 
sulfone 1.28. Acylation with pyrrole acyl chloride gives 1.29, which is converted to 
agelastatins A and B in 3 or 4 steps. Feldman’s late-stage bromination procedure has 
also been adopted in many subsequent efforts.     
 
Scheme 1.2 
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1.2.3 Du Bois’s Synthesis of (–)-Agelastatin A 
Du Bois and Wehn accomplished a robust route towards agelastatin A in 2006.4r  
From optically enriched lactam 1.30, an efficient 3-step route converts this material to  
sulfamate 1.31 (Scheme 1.3).  Using a methodology developed in their group, a 
substrate-controlled rhodium-catalyzed intramolecular aziridination yielded 1.32 as a 
single diastereomer in 95% yield using as low as 0.06 mol% catalyst loading.  Treatment 
of 1.32 with NaN3 allows regioselective attack at C(4) giving 1.33, which after a PhSe 
nucleophilic attack and N-acylation provides a fully functionalized C-ring 1.34, with all 
the requisite stereocenters in place.  The A-ring was then installed via a Paal-Knorr 
pyrrole synthesis while the B-ring was installed via an amidation reaction.  A 4-step 
sequence then converts urea 1.36 to agelastatin A 1.8. 
 
Scheme 1.3 
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1.2.4 Trost’s Stereodivergent Synthesis of Both (+) and (–)-Agelastatin A 
Trost and Dong developed a stereodivergent strategy to access both enantiomers 
of agelastatin A.4j,4m Through the use N-methoxy amide pyrrole 1.37 and carbonate 1.38 
under Pd-catalyzed AAA conditions using standard Trost ligand 1.39 provided ABC ring 
tricycle 1.40 as a single regio- and stereoisomer (Scheme 1.4).  Mechanistically, this 
indicates a double allylic alkylation with the methoxyamide serving as the first 
nucleophile.   A Kresze-type allylic amination reaction then installs N(3) and jumpstarts 
the introduction of the D-ring.  Subsequent acylation of 1.42 with methyl isocyanate 
followed by formal hydration provides 1.43, which is elaborated to (-)-agelastatin A in 2 
steps.  Using the same stereoinducing catalyst 1.39, (+)-agelastatin A was also 
synthesized by sequential Pd-catalyzed AAA methodology. 
 
Scheme 1.4 
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1.2.5 Movassaghi’s Synthesis of (–)-Agelastatins A-F 
The Movassaghi group in 2010 reported the first bioinspired total synthesis of 
agelastatin A and congeners.4s  Their strategy, premised on the isolation of  P-2-AI 
cyclooroidin,5 commenced with chiral pool material D-aspartic acid dimethyl ester 1.44, 
which was converted to pyrrole 1.46 (Scheme 1.5).  This material was readily converted 
to cabinolamide 1.47 in 3 straighforward steps.  Conversion of methyl ester 1.47 to 
imidazolone 1.49 was achieved through formation of a thioester, a Cu-promoted ketone 
synthesis using urea stannane 1.48, and dehydration with HCl in methanol.  Finally, the 
C-ring was introduced via a 5-exo-trig cyclization of imidazolone to the N-acyliminium 
formed from 1.49 under acidic conditions in water.  This overall strategy led to the 
synthesis of all agelastatins with adaptation of some protocols from Pietra.6  
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1.3 Application of N-Acyliminium Intermediates in Bioinspired Total Syntheses 
Iminium ions are important reactive species for the formation of carbon-carbon 
and carbon-heteroatom bonds.  The Mannich and Pictet-Spengler reactions have played 
a dramatic role in the advancement of synthetic organic chemistry in the past century.  
N-Acylation of the iminium ions further enhances its electron-attracting property, 
making N-acyliminium ions much more reactive electrophiles when compared to their 
N-alkyliminium counterparts.   Because of its synthetic utility, several reviews on 
methodologies and applications of N-acyliminium chemistry have appeared in the 
literature.7 This section focuses on representative examples of the utility of                     
N-acyliminium intermediates in synthetic strategies premised on biosynthetic proposals. 
In the biosynthesis of stemoamide 1.54, spermidine 1.51 was proposed to be the 
penultimate biosynthetic precursor.8 The proposal suggests that the azepine ring is 
constructed via iminium ion 1.52 (Scheme 1.6). It also suggests that preorganization of 
the reacting partners in an enzyme pocket is involved in the stereochemical setting step.  
A bioinspired approach based on this proposal was accomplished by Hong and 
coworkers in 2011.8   Their 8-step synthesis with a straightforward coupling of propargyl 
TMS 1.55 and bromo aldehyde 1.56 followed by TBS protection to give 1.57.  
Succinimide substitution followed by NaBH4 reduction furnishes carbinolamide 1.58.  
After extensive experimentation they ultimately found that anhydrous FeCl3 successfully 
induced the formation of N-acyliminium  1.59, which underwent a facile 7-endo-trig 
cyclization to give allene 1.60 containing of  the 7-5 ring system of stemoamide. 
Following a tetrabutylammonium fluoride (TBAF) desilylation of the the TBS group, a 
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remarkable cyclocarbonylation transformation converts 1.61 to lactone 1.62, installing 
the final lactone ring.  A final nickel-catalyzed reaction readily transforms enone 1.62 to 
stemoamide 1.64.       
Scheme 1.6 
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   As part of an attempt to access the fumiquinazoline family of structurally 
related alkaloids, Hart and coworkers9 reported a biomimetic synthesis of ent-
alantrypinone  (ent-1.66). The group proposed that alantrypinone could arise from 
fumiquinazoline F via intramolecular indole cyclization of N-acyliminium 1.64 to form 
bicylcle 1.65 (Scheme 1.7).  This yields alantrypinone 1.66 via an oxidative ring 
contraction reaction of 1.65.  Relying on this biosynthetic proposal, L-tryptophan methyl 
ester 1.67, S-methyl L-cysteine 1.68, and isatoic anhydride 1.69 was coupled in a robust 
4-step sequence to supply 1.70.  Cyclodehydration of 1.70 to iminobenzoxazine 1.71 
was accomplished by treatment with PPh3-I2 in the presence of iPr2NEt.  Exposure to 
lithium trimethyl(phenylsulfido)-aluminate (Li[Me3AlSPh]) effected the rearrangement 
of iminobenzoxazine 1.71 to quinazoline 1.72.  Fmoc deprotection with piperidine 
occurs with concomitant amidation to give 1.73.  Oxidation of 1.73 with m-CPBA 
provided a sulfoxide, which upon heating with triphenylphosphine in benzene furnished 
enamide 1.74.  Trifluoroacetic acid (TFA) promoted the proposed cyclization to bicycle  
formation of 1.75, presumably through an intramolecular nucleophilic attack of the 
indole onto the N-acyliminium.  Oxidative rearrangement of indole 1.75 was effected 
using NBS and TFA in THF/water to give polybrominated indolinone, which following 
hydrogenation utilizing platinum on carbon gave ent-alantrypinone (ent-1.66)  along 
with oxoindole epimer 1.76.  Hart’s 10-step synthesis proceeds in 12% overall yield and 
confirmed the absolute configuration of the natural product. 
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Scheme 1.7 
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CHAPTER II 
BIOINSPIRED TOTAL SYNTHESIS OF AGELASTATIN A* 
 
2.1 Introduction 
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Figure 2.1  The agelastatin family of alkaloids 
 
Agelastatin A (2.1) is a unique tetracyclic member of the growing family of pyrrole-
2-aminoimidazole alkaloids (PAIs)1 that was first isolated by Pietra and co-workers10,6 in 
1993 from the axinellid sponge Agelas dendromorpha  (bioyield 1.2% of dry sponge-150 
                                                
* Part of this chapter is reprinted with permission from [Bioinspired Total Synthesis of 
Agelastatin A” by Reyes, J. C. P.; Romo, D. Angew. Chem. Int. Ed. 2012, 51, 6870-6873. 
Angew. Chem. 2012, 124, 6976-6979.]  Copyright [2012] Wiley-VCH Verlag GmbH & 
Co. KGaA. 
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mg initially isolated) contaminated with a small amount of a dibromo analog, agelastatin 
B (2.2) (Figure 2.1). Exhaustive methylation of the mixture was necessary to effect 
separation and full characterization of agelastatin B as a trimethyl derivative. In 1998, 
two other congeners, agelastatins C (2.3) and D (2.4), were isolated from the West 
Australian axinellid sponge Cymbastela sp. by Molinski and co-workers.11 Twelve years 
later, in 2010, Al Mourabit and co-workers isolated two additional members from Agelas 
dendromopha named agelastatins E (2.5) and F (2.6).12 The intriguing biogenesis of 
these alkaloids, which can be traced back to simple precursors (e.g. oroidin/clathrodin), 
has inspired several biosynthetic proposals but culminated in only one purely bioinspired 
and elegant total synthesis recently described by Movassaghi.4s This is surprising given 
the fact that there are numerous total syntheses reported to date spurred by its 
challenging structure and also the fact that it is arguably the most bioactive member of 
the P-2-AI family reported to date.  
The structure as well as the absolute configuration of the four stereogenic centers 
of the C-ring (8S,7S,5S,4R),10b and conformational preferences of this novel, highly-
fused tetracyclic cytotoxic alkaloid, agelastatin A 2.1, were elucidated by extensive 1D 
and 2D NMR experiments,10a degradation studies, molecular mechanics calculations, 
and exciton splitting for some of its derivatives. Structure-activity relationship studies 
show that unsubstituted OH-C(5), H-N(9), and H-N(3) moieties are essential in the B/D 
transoid configuration for high cytotoxicity. These positions do not tolerate methylation 
or acetylation.  Reductive debromination of the pyrrole  C(13) bromine also leads to a 
significant loss in potency.  This is hypothesized to not necessarily mean the importance 
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of the bromine atom in the aromaticity of the pyrrole but could merely be due to 
conformational change in the tetracycle in its absence.10b 
Agelastatin A 2.1 was first reported to be highly cytotoxic against L1210 mouse 
lymphocytic leukemia cells (IC50 0.097 µM), its doxorubicin-resistant variant (IC50 1.37 
µM) and against KB nasopharyngeal tumor cells (IC50 0.220 µM).6 It also exhibited 
potent anti-tumor activity against murine P388 leukemia cells (IC50 0.152 µM) and a 
panel of human cancer cell lines (IC50 0.097-0.703 µM) including pancreas (IC50 0.261-
0.498 µM) and breast adenocarcinoma (IC50 0.097-0.161 µM), CNS glioblastoma (IC50 
0.111-0.243 µM), lung large cell (IC50 0.105-0.120 µM), colon adenocarcinoma (IC50 
0.164-0.258 µM), prostate carcinoma (IC50 0.123-0.170 µM), neuroblastoma (IC50 0.352 
µM), and anaplastic thyroid (IC50 0.703 µM) and pharynx squamous carcinoma (IC50 
0.223 µM).13  Antiangiogenic activity against human umbilical vein endothelial cells 
(HUVEC) was also observed.14 Most recently, it was found to inhibit osteopontin 
(OPN), a glycoprotein implicated in aggravating neoplastic transformation, cancer cell 
progression, and metastasis.  Its antimetastatic activity stems from inhibition of OPN-
mediated malignant transformation through inhibition of Wnt signaling and prevention 
of progression of the cell cycle.15 It selectively inhibits glycogen synthase kinase-3$ 
(GSK-3$) over other kinases thought to be associated with Alzheimer’s disease.  As a 
GSK-3$ inhibitor, it could also act as a potential insulino-mimetic and have possible 
antidiabetic properties.16 Significant insecticidal activity against larvae of the beet army 
worm and the corn root worm has also been determined.4  Despite these promising 
biological activities, the cellular receptor of agelastatin has not been determined.  
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There are two biosynthetic proposals put forth in literature for the biosynthesis of 
agelastatin A.  Pietra and co-workers10a, in 1993, envisioned that a hymenidine-like 
precursor 2.7, through an an enzyme driven C(8) attack at C(4), forms the C(4)-C(8) 
bond of the C-ring (Scheme 2.1).  The developing partial positive charge at C(7) of 2.8 is 
then quenched by the pyrrole N(12) nitrogen to complete the C(7)-N(12) bond of the B-
ring of 2.9. Refunctionalization at C(4) and C(5) possibly through the intermediacy of 
imidazolone 2.10 followed by an acid catalyzed hydration then gives agelastatin A. 
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In 2001, Al-Mourabit and Potier17 proposed the biosynthesis of agelastatin A 
starting with the union of a 5-bromopyrrole-2-carboxylic acid 2.11 and a tautomer of  3-
amino-1-(2-aminoimidazolyl)-prop-1-ene (AAPE) 2.12 giving rise to a linear agelastatin 
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precursor 2.13 (Scheme 2.2).  Oxidation of the 2-aminoimidazole core then gives 2.14 
and creates an electrophilic center, which undergoes a 5-exo-trig cyclization forming 
C(4)-C(8) bond to give 2.15. Nucleophilic attack of the pyrrole nitrogen N(12) at C(7) 
through a 6-exo-trig cyclization gives tetracycle 2.16, which after tautomerisation, C(5) 
hydration, N(1) methylation, and C(2) hydrolysis furnishes agelastatin A.  The first 
cyclization mode proposed herein was later on validated in 2007 by the isolation of the 
dimeric oroidin natural product, Nagelamide J (cf. 2.21), by Kobayashi and co-
workers.18  
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In 2010, Movassaghi and co-workers4s, envisioned a biosynthesis proposal 
starting from the unnatural C(7) enantiomer ent-cyclooroidin derivative 2.18 (Scheme 
2.3).  They reason that downstream biosynthetic enzymes may preferentially bind to ent-
cyclooroidin for the synthesis of agelastatins.  Early installation of the N(1) methyl, C(2) 
hydrolysis, and C(8) oxidation then gives rise to an N-acyliminium intermediate 2.19 
that undergoes C-ring cyclization  followed by nucleophilic trapping with water to give 
agelastatin A. 
 
Scheme 2.3 
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The C-ring, which contains all four stereogenic centers found in the natural 
product, is clearly the most challenging aspect of this molecule.  In fact, most previous 
synthetic strategies focused on building the functionalized cyclopentane C-ring followed 
by subsequent construction of the B and D rings. As part of our efforts to investigate the 
biogenesis of PAIs,19 this chapter describes our synthetic studies that ultimately led to a 
concise, bioinspired approach to agelastatin A that is premised on the isolation of the 
structurally related natural product, nagelamide J (cf. 2.21).18 
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Two distinct and plausible biosynthetic presursors of agelastatin A isolated to 
date are cyclooroidin 2.2020 and nagelamide J 2.2118 (Figure 2.2). These natural products 
each support a different order of B-ring and C-ring formation. Although the absolute 
configuration of 2.21 is unknown, it is worth noting that 2.20 bears the opposite 
configuration at C(7) compared to agelastatin A. Movassaghi recently described a 
strategy premised on formation of an ent-cyclooroidin-like compound (cf. 2.18)  
followed by C-ring cyclization to deliver (–)-agelastatin A. In contrast, the synthetic 
strategy described herein highlights an alternative biogenetic pathway inspired by the 
nagelamide J structural motif suggesting a biogenetic sequence involving initial C-ring 
formation followed by B-ring formation.  
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Figure 2.2  Agelastatin A and pre-agelastatin motifs in other P-2-AIs  
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Our bioinspired approach to agelastatin A was also guided by our previous 
experience with the ambivalent reactivity of the 2-imidazolone nucleus, observed in our 
studies toward dimeric P-2-AIs (Figure 2.3).21   The core structure 2.23 is quite 
nucleophilic and can react with an electrophile, with the concomitant formation of a 
reactive N-acyliminium 2.24, which could then be trapped subsequently with a 
nucleophile. The overall process leads to a formal addition across the imidazolone olefin 
providing 2.25.    
 
HN NH
O
HN NH
O
E
HN NH
O
ENuE+ Nu
2.23 2.24 2.25  
 
Figure 2.3  Ambivalent reactivity of 2-imidazolones  
 
In our efforts towards the total syntheses of dimeric oroidin alkaloids 
palau’amine (cf. 1.11) and axinellamines (cf. 1.10), reaction of imidazolone 2.26 with 
dimethyldioxirane leads to epoxide 2.27 (Scheme 2.4).  This then cleaves through 
electron pushing from the nitrogen to give N-acyliminium 2.28, which in the absence of 
a nucleophile, undergoes tautomerisation to give enamide 2.29. We then take this 
intermediate to a chlorination-ring-contraction sequence to give the 5-5 spiro-ring core 
2.31 found in palau’amine and other dimeric oroidin alkaloids. 
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Scheme 2.4 
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This imidazolone reactivity is in stark contrast to what is commonly invoked for 
the biogenesis of these targets, wherein an oxidized imidazolone or aminoimidazole 
serves as an electrophile in subsequent cyclization events.10a,17 Based on this reactivity 
pattern we put forth our own biosynthetic proposal starting from a keramadine analog 
2.31 (Scheme 2.5). Keramadine22 2.22 is the only isolated, monomeric PAI, also from an 
Agelas sponge, known to posses a stable Z-configured olefin and notably bears the 
requisite N1-methyl group found in the agelastatins.  Early hydrolysis at C(2), followed 
by oxidation at C(8) gives carbinolamide 2.32. N-acyliminium formation then provides 
2.33 ready for nucleophilic attack by the imidazolone in a 5-exo-trig fashion or through 
its resonance structure 2.34 undergo a 4! electrocyclization process.  Either of this 
process leads to a conjugated N-acyliminium intermediate 2.35, which can be trapped by 
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the pendant pyrrole nitrogen. Overall this leads to sequential C and B ring formation via 
an N-acyliminium-initiated, diastereoselective, bis-cyclization cascade exploiting the 
‘umpolung’ reactivity of the imidazolone nucleus. Following a hydration step, this 
sequence provides agelastatin A. 
 
Scheme 2.5  
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Based on the above biosynthetic proposal, our retrosynthetic strategy starts with 
a hydration step from ‘dehydroagelastatin A’ 2.36 to install the stable carbinolurea 
moiety in the target (Scheme 2.6).  Two strategic bond disconnections on the C and B 
rings, at the C4-C8 and C7-N12 bonds, reveal a linear precursor 2.37 with pendant A 
and D rings. We envisioned that a key N-acyliminium intermediate could be derived 
from 2.37, utilizing a Brønsted or Lewis acid. The C6-C7 Z-olefin was introduced to 
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exert conformational bias and assist in the formation of the C4-C8 bond via a 5-exo-trig 
cyclization or via a a Nazarov 4! electrocyclization. The Z-configured olefin of the key 
cyclization precursor 2.37 will then be introduced using a Lindlar reduction of alkyne 
2.38, which in turn arises from the coupling of an appropriate imidazolone alkyne 
fragment and a pyrrole carboxamide fragment. 
 
Scheme 2.6 
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With the synthetic plan layed out, the rest of this chapter presents our synthetic 
investigations that ultimately led to a concise ‘bio-inspired’ total synthesis of agelastatin 
A utilizing an imidazolone intermediate bearing an allylic N-acylcarbinolamide. This 
synthesis enabled cellular receptor isolation studies through synthesis of designed 
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derivatives bearing novel sites for probe attachment, taking some lessons from literature  
SAR data. These investigations are detailed in chapter III. 
Retrosynthetic analysis of key coupling adduct 2.38 led us to two different 
disconnections detailed in Scheme 2.7.  The syntheses of the possible fragments 2.39-
2.44 for this coupling reaction are detailed in the next two subsections. 
 
Scheme 2.7 
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2.2 Syntheses of the Imidazolone Fragments 
 The imidazolone fragment synthesis starts with a modified literature procedure 
that involves the condensation of N-methyl urea 2.45 and tartaric acid 2.46  (Scheme 
2.8). Modification in the procedure included the use of 95-98% sulfuric acid (H2SO4) 
instead of 16% H2SO4 decribed in the literature.23 After heating at 80 °C for 3 hours, 
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precipitation in ice water lead to isolation of 2.47 as tan solids.  Regioselective 
placement of the methyl group at N1 was verified by 1D NOE correlations (Scheme 
2.8).   The 1D NOE difference spectra showed that irradiation of either N3-H or C4-H 
shows enhancement of the other.  Irradiation of the N1-Me protons, on the other hand 
did not show any enhancement of other proton signals as expected since it is not within 
proximal distance to other protons within the compound. While the values of 2.52% and 
3.73% enhancements do qualitatively prove the proximity of N3-H and C4-H, these are 
low values due to the limitations of 1D NOESY measurements and some relaxation of 
signal during the mixing time is expected.    
 
Scheme 2.8 
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 The regioselectivity was further verified by correlation of the proton chemical 
shifts with literature values of both plausible regioisomers (Table 2.1).23a  While the 
observed chemical shift of C4-H does not match well with either compounds, the 
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chemical shift of N1-CH3 (3.28 ppm) and N3-H (10.83 ppm)  in 2.47 does indeed 
correlate better with 1-methyl-2-oxo-imidazoline-5-carboxylic acid.  
 
Table 2.1 Characterization of 2-imidazolone 2.47. 
#  (ppm) Compound 
NH =CH NCH3 
3-Methyl-2-oxo-imidazoline-5-carboxylic acid 10.33 7.16 3.08 
1-Methyl-2-oxo-imidazoline-5-carboxylic acid 10.60 7.13 3.25 
Compound 2.47 10.83 7.27 3.28 
 
With the N1-methyl imidazolone acid 2.47 in hand, the next challenge was to 
install the appropriate bromine pendant through a decarboxylative bromination (Scheme 
2.9).  This will be coupled to an appropriate alkyne via a Sonogashira cross coupling 
reaction to provide imidazolone alkyne fragments 2.49a and 2.49b.  
 
Scheme 2.9 
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 Several procedures were screened for the decarboxylative bromination step 
(Table 2.2).  These however did not produce any of the desired product 2.48 and the 
crude 13C NMR showed the loss of the olefinic carbon signals in most cases.  The only 
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promising result was that of entry 2 where the pyridine nitrogen is attached to the 
imidazolone core as a pyridinium salt providing 2.50a.  This product was verified my 
mass spectrometry and NMR spectroscopy.   From these results, it is apparent that the 
imidazolone olefin is still quite nucleophilic even in the presence of a conjugated acid 
moiety.  The absence of olefinic carbon signals indicates a bis-bromo product or a bis-
aminal product of the general structure 2.50b.  This possibly occurs through a 
mechanism similar to the addition of a bromine across an olefin and is a consequnce of 
the dual reactivity of the imidazolone core as discussed previously.    The bis-aminal 
product is the addition of water to the N-acyliminum formed after extrusion of the 
bromines.  These proposed structures, however, were not unambiguously assigned. 
 
Table 2.2 Screening of conditions for decarboxylative bromination. 
NH
N ON
Br
NH
N OBr
NH
N OHO2C
decarboxylative 
bromination
Me Me
2.47 2.48
Me
NH
N O
R
R
O
HO
Me
R = Br or OH
2.50a 2.50b
 
Entry Conditions Outcome 
1 i. KOH, AgNO3, H2O; ii. Br2, CCl4 Single product 16% yield; 
No olefinic 13C signal 
2 PyHBr3, CH2Cl2 Product 2.50a 
3 LiOAc, NBS, MeCN/H2O, 50 °C Multiple products; 
No olefinic 13C signal 
4 K2CO3, NBS, DMF Multiple products;  
No olefinic 13C signal 
5 Br2, AcOH 2 products;  
No olefinic 13C signal 
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The pyridium product 2.50a was then tested for bromine substitution using 
sodium bromide (NaBr) in water and DMSO as solvents (Scheme 2.10).   However, the 
starting material seemed to be resistant to substitution and is stable to bromide 
nucleophiles and the conditions tested did not yield any bromoimidazolone 2.48. 
 
Scheme 2.10 
 
NaBr, H2O
NaBr, DMSO
NH
N ON
Br
NH
N OBr
Me
2.48
Me
2.49
 
 
The next strategy then relied on more classical functional group interconversion 
of an acid moiety to an alkyne (Scheme 2.11).  This involved an esterification step, a 
reduction step to alcohol 2.53, oxidation to aldehyde 2.54 and finally a homologation to 
yield alkyne 2.55.  
Scheme 2.11 
 
NR
N OHO2C
H3C
NR
N OMeO2C
H3C
NR
N OHOH2C
H3C
NR
N OOHC
H3C
NR
N O
H3C
2.51 2.52 2.53
2.54 2.55  
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Conversion of acid 2.47 to methyl ester 2.56 via a Fischer esterification with 
methanol proved not to be as straightforward as it seemed (Table 2.3).  A mixture of 
thionyl chloride (SOCl2) in methanol provides hydrochloric acid (HCl) that catalyzes a 
Fisher esterification to yield methyl ester 2.56.  However, it was found that with 1.5 – 
3.0 equivalents of thionyl chloride, the reaction required heating to effect conversion to 
product 2.56 with concomitant decarboxylation byproduct 2.57 (entries 1-4). While high 
tempreratures was necessary for dissolution, it also promoted the decarboxylation 
pathway.  A mixture of dimethyl formamide (DMF) and methanol (MeOH), while 
making the reaction more homogenous at room temperature (entry 5), however, provided 
no reaction product at 23 °C and even at 50 °C indicating that an excess of methanol is 
necessary to push the reaction forward.  Sulfuric acid (H2SO4) and acetyl chloride 
(AcCl) were then screened as an alternative to thionyl chloride but still led to about a 1:1 
mixture of the desired methyl ester 2.56 and decarboxylation product 2.57 (Entries 6 and 
7).  Lowering the equivalents of sulfuric acid while maintaining reflux conditions or a 
temperature of 60 °C either led to no reaction or still a mixture of products (Entries 8-
10).  Finally, it was found that 50 equivalents of sulfuric acid promoted the reaction 
effectively producing only the desired esterification product 2.56 in 41% yield (Entry 
11).  
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Table 2.3 Screening of conditions for Fischer esterification. 
 
NH
N OHO2C
H3C
NH
N OMeO2C
H3C
2.47 2.56
reagent
MeOH NH
N OMeO2C
H3C
2.57
+
 
 
Entry Conditions Temp. Time Ratio 2.56:2.57 
1 SOCl2 (2 equiv.) reflux 12h ~1:1 
2 SOCl2 (2 equiv.) 55ºC 12h ~1:1 
3 SOCl2 (3 equiv.) 52ºC 3h ~1:1 (45% conversion) 
4 SOCl2 (1.5 equiv.) 60ºC 12h 4:5 (74%conversion) 
5 SOCl2 (2 equiv.) 
(DMF/MeOH 3:1) 
rt 
42ºC 
50ºC 
6h 
6h 
10h 
No reaction 
No reaction 
No reaction 
6 AcCl (20 equiv.) reflux 12h ~1:1 
7 H2SO4 (20 equiv.) reflux 12h ~1:1 
8 H2SO4 (0.1 equiv.) reflux 12h No reaction 
9 H2SO4 (0.6 equiv.) reflux 6h 2:3 (15% conversion) 
10 H2SO4 (10 equiv.) 60ºC 12h ~1:1 
11 H2SO4 (50 equiv.) rt 12h 1:0 (41% yield) 
 
With ester 2.56 in hand, the next step was protection of imidazolone N(3) with a 
tosylethyl group, a protecting group popularized by the Romo group for the ease of 
preparation of the required reagent, tosylethyl mesylate, and facile removal through the 
use of a variety of bases.  We also explored the dimethoxybenzyl (DMB) protecting 
group.   
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Scheme 2.12 
 
NH
N OHO2C
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2)  DIBAl-H, CH2Cl2, -78 ºC
3) MnO2, CH2Cl2, 23 ºC
(85%, 3 steps)
NTse
N OOHC
P
OO
MeO
MeO
N2
1)  NaOMe, MeOH/CH2Cl2
NTse
N
O
(56%)
2) ZnI2, CH(OEt)3 110 ºC (84%)
EtO
EtO
Me Me
Me
2.58
2.59
2.47
-40 °C ! 23 °C
 
 
We eventually discovered that esterification acid 2.47 was easily achieved under 
basic conditions (K2CO3) using methyl iodide while in the same pot protecting N(3) with 
a tosylethyl moiety using the same base (Scheme 2.12).  Conversion of resulting methyl 
ester to aldehyde 2.58 was accomplished in a two-step process involving  reduction with 
DIBAl-H, and oxidation with manganese(IV) oxide (MnO2). Modified Seyferth-Gilbert 
conditions using Ohira-Bestmann reagent24 and sodium methoxide25 in a 1:1 mixture of 
methanol and dichloromethane  as  solvent  gave the desired alkyne.  Addition of 
dichloromethane as cosolvent helped solubilize the aldehyde starting material.   This 
transformation required low temperatures with extended reaction times to give the best 
yields.  Overall, the conversion of 2.47 to 2.58 occurs in 85% yield over three-steps.  A 
subsequent Zn(II)-mediated acetalization26 furnished the targeted alkynyl acetal 2.59, 
and this entire 5-step sequence could be readily performed on multigram scale.  DMB 
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protected alkyne 2.44 was also synthesized in the same manner (Scheme 2.13). 
Subsequent acetalization and formylation (n-BuLi/DMF) of this intermediate resulted in 
the requisite imidazolone fragments 2.40 and 2.41, respectively, to be screened for the 
key coupling reaction described in section 2.4. 
 
Scheme 2.13 
 
NDMB
MeN
O
EtO
EtO
     ZnI2, CH(OEt)3 
      µw 80 ºC, 86%
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NDMB
MeN
O
O
H
NDMB
MeN
O
2.44
2.40
2.41  
 
2.3 Syntheses of the Pyrrole Fragments 
  The synthesis of bromopyrrole fragment 2.61 starts with trichloroacetyl pyrrole 
2.60 (Table 2.4).  Amidation reaction of 2.60 with ammonia led to quantitative 
conversion to pyrrole amide 2.39.  However, regioselective bromination of 2.39 proved 
to be problematic leading to products 2.60a, 2.60b, and 2.60c (Table 2.4).  Sub-
stoichiometric amounts (0.3 equivalents) of brominating agents were used in the 
screening process to reduce the risk of overbromination.  Once a pyrrole position is 
brominated, it results to activation towards electrophilic aromatic bromination.  
Screening of solvents with N-bromosuccinimide (NBS) revealed that THF/MeOH and 
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acetonitrile both gave a ratio of 3:1:0 in favor of the desired product ----.  On the other 
hand, using methanol also gave bis-brominated product 2.60c.    THF/MeOH proved to 
be superior to acetonitrile in terms of solubilization of the starting material.  Using other 
sources of electrophilic bromine, namely tetrabromocyclohexadienone and pyridinium 
bromide perbromide (entries 4 and 5) gave inferior results.  Further optimization of entry 
3 was done by slowing down the bromination process by lowering the reaction 
temperature (entries 6-8).  A 5-hour reaction at -5 °C was found to be optimal giving a 
4:1:0 ratio of the bromopyrrole products.  Lowering the reaction temperature further, 
only resulted with inferior ratio of products.   While the optimized ratio of products is 
reasonable to get sufficient quantities of the desired product 2.60a, purification of the 
mixture proved to be difficult.  
 
Table 2.4 Electrophilic aromatic substitution of pyrrole carboxamide 2.39. 
 
NH
O
NH2
NH
O
CCl3
NH3, THF
conditions
NH
O
NH2
Br
NH
O
NH2
NH
O
NH2Br
Br
Br
5
4
3
299%
5
4
5
4
2.60 2.39
2.60a 2.60b 2.60c  
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Table 2.4 Continued. 
 
Conditions Product Ratio  
(2.60a : 2.60b : 2.60c) 
NBS (0.3 equiv), MeOH, 0ºC to rt 2:1:1 
NBS (0.3 equiv), CH3CN, 0ºC to rt 3:1:0 
NBS (0.3 equiv),  THF/MeOH, 0ºC to rt  3:1:0 
Tetrabromocyclohexadienone (0.3 equiv) 0ºC to rt 
THF/MeOH 
1.67:1:0.6 
Pyridinium bromide perbromide (0.3 quiv) 0ºC to rt 
THF/MeOH 
0.8:1:0.2 
NBS (0.3 equiv),  THF/MeOH, -5ºC (5h) to rt 4:1:0 
NBS (0.3 equiv),  THF/MeOH, -78ºC (5h) to rt 2.5:1:0.3 
NBS (0.3 equiv), THF/MeOH, -30ºC (7days) 3.2:1:0.5 
 
 
  Since regioselectivity of electrophilic aromatic bromination is highly dependent 
on the overall electronics of the aromatic ring, we sought to decrease the electron 
withdrawing effect of the acyl group of the amide.  To this end, reaction of O-
methylhydroxylamine hydrochloride salt with trichloroacetyl pyrrole 2.60 using 
triethylamine as solvent led to quantitative conversion to N-methoxy amide 2.61 
(Scheme 2.14).4j  Reaction of  2.61 with NBS in THF/MeOH led to regioselective 
bromination of the pyrrole 5-position in 96% yield.  
 
 
 
 
 
   
 35 
Scheme 2.14 
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O
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 NH2OMe.HCl
Et3N, 80ºC
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O
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2.60 2.61 2.62
 
 
Chemoselective formylation of N-methoxy amido pyrrole 2.62 was successfully 
accomplished with 2-chloro-4,6-dimethoxy-1,3,5-triazine (CDMT), formic acid, 4-
(dimethylamino)pyridine (DMAP) and  N-methylmorpholine (NMM) to give formylated 
compound 2.42 (Scheme 2.15).  Interestingly, a similar N-formyl amide 2.63 was 
isolated from the marine sponge Agelas oroides.27  
 
Scheme 2.15 
 
2-chloro-4,6-dimethoxy-1,3,5-triazine (CDMT)
HCOOH, DMAP, NMM, CH2Cl2
NH
O
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N
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O
H
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NH H
N H
O O
- a pyrrole derivative 
isolated from Agelas oroides
2.62 2.42
2.63
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  Acetalization of amides 2.62 and 2.39 leads to other possible pyrrole fragments 
for the key coupling reaction (Scheme 2.16).   Surprisingly, 2.62 was not able to react 
with triethylorthoformate to give any of the desired product 2.64.  However, amide 2.39 
successfully reacted with triethylorthoformate in acetic acid to give acetal 2.43, in low 
conversion albeit easily separable from the starting material.  Heating of this reaction led 
to multiple products.  The use of potential pyrrole fragments 2.42 and 2.43 are described 
in section 2.4. 
 
Scheme 2.16 
 
CH(OEt)3, AcOH NH
O
H
N OEt
OEt
12%
NH
O
NHOMe
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2.62
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O
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2.4 Coupling of Fragments 
  With the proposed pyrrole amide and alkynyl imidazolone fragments 
synthesized, we continued with our studies on the key coupling reaction leading to a 
product containing all the requisite carbons found in agelastatin A.  Our first 
disconnection relied on the coupling of imidazolone alkyne 2.68 onto activated carbonyl 
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equivalents 2.66 and 2.67 (Scheme 2.17).   Screening of conditions revealed that the 
carbonyl equivalents 2.66 and 2.67 were prone to hydrolysis giving amides 2.62 and 
2.39, respectively.  In some cases where the desired C-C bond was formed, only the 
formal formyl transfer adduct 2.41 was isolated.    
 
Scheme 2.17 
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  Alternative disconnection of the C(8)-N(9) bond leads to pyrrole fragments 2.39 
and alkynyl imidazolone fragments 2.40 and 2.41(Scheme 2.17).  Amide 2.39 was 
expected to behave as a vinylogous urea, due to delocalization of pyrrole N electrons, 
and thus have enhanced nucleophilicity. Activated acyl equivalents 2.70 and 2.71, on the 
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other hand served as the electrophiles upon activation with Lewis or Brønsted acids.  
After extensive experimentation with a variety of activators, we found that amide 2.39 is 
quite inert or that the addition reaction is reversible.  In most cases, reaction conditions 
only returned starting materials or some decomposition of the imidazolone fragments as 
well as hydrolysis of 2.71.   
Scheme 2.18 
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  At this point, focus was directed towards searching for an appropriate nitrogen 
nucleophile to alkynyl imidazolone 2.40, which could be accessed in gram quantities.  
After screening several nitrogen nucleophiles and Lewis acids, successful coupling of 
fragments was finally achieved using N-methoxy amide 2.62 and alkyne acetal 2.40 
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using SnCl4 as a catalyst (Scheme 2.19). A substoichiometric amount (0.25 equiv) of 
SnCl4 and a 3 h reaction time provided the best results in terms of avoiding further 
decomposition and enabling optimal recovery of unreacted alkynyl acetal 11 and pyrrole 
amide 12. The ‘alpha effect’ of the adjacent methoxy group on the amide nitrogen 
allowed regioselective reactivity of the amide nitrogen over the pyrrole nitrogen toward 
the oxocarbenium 2.71 to give the desired coupling adduct 2.72.  
 
Scheme 2.19 
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2.5 Synthesis of N-Acyliminium Cyclization Precursor: Investigation of the 
Proposed Key Step 
  Lindlar reduction of coupling adduct 2.72 provided bis-cyclization precursor  
2.73 (Scheme 2.20).   We sought not to optimize this reaction at this point and 
investigated the proposed N-acyliminium biscyclization cascade.   Treatment of 
precursor 2.73 with SnCl4 surprisingly did not yield the desired N-acylimminium 2.74, 
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which is supposed to undergo the 5-exo-trig cyclization followed by the 6-exo-trig 
cyclization.  Instead of delivering dehydroagelastatin 2.76, the compound broke apart 
into two fragments releasing pyrrole amide 2.62 and oxocarbenium 2.77, which in turn 
hydrolysed and isomerized to enal 2.78.  Reduction cleavage of the N-methoxy group in 
2.72 was postponed since we reasoned that aside from keeping the nitrogen protected, it 
could also serve as a suitable coordinating atom for further activating N-acyliminium 
2.74.   As the results showed, bis-coordination of the Lewis only activated 2.73 towards 
oxocarbenium formation instead.  The methoxy group also lowers the pKa of amide 
2.62, making its conjugate base a weaker base and therefore a better leaving group.  
 
Scheme 2.20 
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  To further verify that an oxocarbenium 2.71 (Scheme 2.21), instead of an             
N-acyliminium 2.79 is formed from an N-methoxycarbinolamide motif, 2.72 was 
subjected to tin(IV) tetrachloride (SnCl4) and the resulting intermediate (either 2.71 or 
2.79) was then trapped with allyl TMS. NMR or LCMS analysis found none of the 
expected product 2.80 from N-acyliminium 2.79. Not surprisingly, the reaction yielded 
only product 2.81, which was observed in 80% yield, as a result of allyl TMS trapping of 
oxocarbenium 2.71.  The reaction also returned pyrrole amide coupling partner 2.62. 
 
Scheme 2.21 
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  To avoid the detrimental effects of the N-methoxy group in our proposed key 
step, we elected to reductively cleave the N-methoxy bond earlier than what we 
originally planned.  To this end, coupling adduct 2.82, now bearing an N-tosylethyl 
protecting group, was subjected to samarium (II) iodide (SmI2) to cleave the N-O bond 
(Scheme 2.22).  Performing this reaction at -20 °C prevented debromination of the 
pyrrole as a byproduct, which occurs when the reaction is done at 23 °C.  Inconsistencies 
in conversion, yield, and selectivity of the Lindlar reaction in the formation of 2.84 due 
to catalyst inactivity or overactivity was solved through the use of 2,2$-
(Ethylenedithio)diethanol as a palladium poison.  As low as 10 ppt of poison was 
sufficient to effect a more consistent reaction yield and chemoselectivity,  furnishing 
biscyclization precursor 2.84. Screening of manufacturers of Lindlar’s catalyst revealed 
that Strem Chemicals consistently gave active palladium catalysts when compared to 
Sigma-Aldrich.  The use of a 1:1 mixture of THF-methanol was also key in 
solubilization of the starting material 2.83, giving a faster conversion to the desired 
alkene product  2.84.   X-ray crystallographic analysis28 of this intermediate confirmed 
the Z-olefin configuration and the chemoselective addition of the amide nitrogen over 
the pyrrole nitrogen in the coupling step.  
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Scheme 2.22 
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 Treatment of 2.84 with Brønsted or Lewis acids, however, still did not deliver the 
desired biscyclization adduct dehydroagelastatin A 2.85.   Interestingly, formation of         
N-acyliminium 2.86 was favored and underwent a facile 5-exo-trig cyclization or a 
Nazarov 4! electrocyclization involving the pseudoaromatic imidazolone (Scheme 
2.23).29  The  deep red solution formed in this process was  postulated at this point to be 
due to the highly conjugated  N-acyliminium intermediate 2.87.  The 6-exo-trig attack of 
the pyrrole nitrogen, however, did not occur and 2.87 seemed to be stable until quenched 
with a nucleophile (e.g. water) to give monocyclized adduct 2.88. Quenching with 
methanol or ethanol gives the corresponding methoxy and ethoxy carbinolamines, 
respectively (not shown). Formation of the C-ring was quite facile as complete 
conversion occurred in < 5 min at low temperatures and delivered three contiguous 
stereocenters with a relative configuration corresponding to the agelastatins and 
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nagelamide J.  However, the second cyclization envisioned to complete the synthesis, 
involving nucleophilic addition of the pyrrole nitrogen to C7 of the extended                   
N-acyliminium 23, did not proceed under a variety of conditions including prolonged 
reaction times, addition of non-nucleophilic bases, or exposure to elevated temperatures.  
Under most conditions, the dark red intermediate, which is presumably N-acyliminium 
2.87 was easily regenerated from 2.88 with both Lewis and Brønsted acids and again 
persisted until quenched with a nucleophile (e.g. water, methanol) leading back to 
carbinolamine 2.88.  
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Conformational analysis of intermediate 2.87 suggests that the C6-C7 olefin is 
out of plane with respect to the N-acyliminium by ~25° resulting in a low degree of 
conjugation which in turn is responsible for the low electrophilicity at C7 (Scheme 
2.24).30 This may also explain why intermolecular addition of nucleophiles occurred 
exclusively at the more electrophilic C5 carbon. Moreover, DFT calculations31 predicted 
that products 2.90 and 2.91 arising from nucleophilic trapping at C7 were energetically 
disfavored by ~2 kcal/mol relative to trapping at C5.  
 
Scheme 2.24 
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N-acyliminium precursor 2.84 (Scheme 2.25) was also found to be highly 
sensitive to even traces of Brønsted acids (e.g. traces of HCl in CDCl3).  This occurs 
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with a transient persistence of faint red color that rapidly disappears within seconds.  It 
undergoes facile cyclization with the ethanol byproduct of N-acyliminium formation 
readily quenching 2.87 to form ethoxy cabinolamine 2.92 and returns the acidic proton 
for another catalytic cycle.   Lewis acids on the other hand traps the ethoxy group that is 
cleaved off of precursor 2.87, and allows the formation of either 2.88 or 2.92, with water 
or ethanol as nucleophiles, respectively.  
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  The full characterization as well as confirmation of the relative stereochemistry 
of the newly formed C-ring was established through a combination of NMR studies and 
DFT calculations of 1H NMR coupling constants (Table 2.5). The cis-fused 
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configuration of on the 5-5 ring system in 2.93 (Scheme 2.26) was established through 
the NOESY correlation of C(4)-H and C(5)-OMe.  The C(4)-C(8) connectivity that 
closed the C-ring was verified though COSY correlations of C(4)-H and C(8)-H as well 
as 1H-13C correlations of C(7)-H to C(4) as well as C(4)-H to C(7).  These 2D NMR 
studies however could not verify the trans relationship between C(4)-H and C(8)-H.  To 
this end, the experimental 1H-1H coupling constants were then compared to what is 
expected when these protons are cis or trans and is compared to predictions for products 
2.89 and 2.92.  Predictions were based on the dihedral angles of these compounds and 
comparison with the experimental.   The predictions of the Karplus plot gave very broad 
and similar ranges of 6.0-10.3 Hz and 6.5-11.6 Hz despite the large difference in 
dihedral angles 140.7° and 23.7°, respectively.  DFT calculations using Gaussian 09 
(B972/6-311g(2d,p)), on the other hand, was quite useful and product 2.92 closely 
matched the experimental coupling constants.  Based on this evidence, C(4)-H and C(8)-
H was established to be the desired trans configuration. 
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NH
N
NH
N
O
O
Br
Me
H
MeO
H
HMBC NOESY
COSY
NH
N
NH
NH
O
O
Br
HO
H
Me
NH
N
NH
NH
O
O
Br
HO
H
Me
2.89 2.92
8
4
8
4
2.93
8
5
4
 
 
   
 48 
Table 2.5 Characterization of monocyclized adduct 2.89. 
  2.89 2.92 
C(4)-H -- C(8)-H dihedral angle 140.7 º 23.7 º 
3J , (Karplus Plot) 6.0-10.3 Hz 6.5-11.6 Hz 
#, 3J [C(4)-H -- C(8)-H] 
(B972/6-311g(2d,p)) 
3.37 ppm, 2.6 Hz 
4.61 ppm, 2.6 Hz 
3.66 ppm, 5.6 Hz 
5.00 ppm, 5.6 Hz 
#, 3J [C(4)-H -- C(8)-H] 
 (experimental, CD3OD) 
3.67 ppm, 2.0 Hz 
4.66 ppm, 2.0 Hz 
 
 
We were intrigued by the observed intense red color during the first cyclization 
event, which occurs immediately upon addition of acid even at low temperatures.  Given 
the absorption of light in the visible region, we suspected that the color may be due to a 
charge transfer complex involving the N-acyliminium intermediate 2.87. We utilized 
Time-Dependent Density Functional Theory (TD-DFT) calculations to analyze excited 
states of this charged intermediate and simpler sub-structures using B3LYP and X3LYP 
hybrid functionals.32  We compared these values with those extracted from the 
experimental UV-VIS spectra of this colored intermediate and related simpler sub-
structures. These studies revealed that the red color of intermediate 2.87, is likely due to 
a !"!* transition between the HOMO, which is composed mostly of orbital 
contributions from the bromopyrrole amide moiety and the LUMO, which is composed 
mostly of orbital contributions from the N-acyliminium moiety (Figure 2.4). 
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HOMO
LUMO
! " !#
transition
 
Figure 2.4 Calculated HOMO and LUMO of the red-colored N-acyliminium 2.87 and 
the !"!* transition proposed to be responsible for this color based on TD-DFT 
calculations. Isovalue for surface = 0.04. 
 
Given that the stereochemical setting step in the synthesis is an acid-catalyzed C-
ring formation, which sets three out of four contiguous stereocenters in a highly 
diastereoselective fashion, we envisioned that the use of chiral acids should set the 
absolute stereochemistry of the core C-ring.  Initial screening of chiral acids shown in 
Table 2.6 revealed the superiority of BINOL-derived phosphoric acids 2.95 with 3,3’-
bistriphenylsilyl-substituted BINOL phosphosphoric acid 2.95c giving the best 
enantiomeric excess of 74% (enantiomeric ratio 87:13).  Due to limitations in available 
chiral columns in our laboratories, enantiomeric excess was established by HPLC 
analysis of the deprotected product 2.89.  Erosion of about 10% ee was observed during 
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purification of 2.89. Further screening of catalysts and conditions are necessary to 
optimize the enantiomeric excess and yield highly enantiopure synthetic natural product. 
 
Table 2.6. Screening of chiral Brønsted acids. 
 
NTse
N
NH
NH
O
O
Br
OEt
chiral acid, CH2Cl2 NR
N
NH
NH
O
H
O
Br
OH
Me Me
 -30 ºC to 20 °C
KHMDS
THF, 60 ºC
2.88: R = Tse
2.89: R = HTsTse =
O
O P
O
OH
R
R
O
S
O
O
HO
2.93 (+)-CSA
OO
O OH
OHO
O
O
2.94 (-)-Dibenzoyl tartaric acid
2.84
2.95a R = Ph(CF3)2
2.95b R = Ph(iPr)3
2.95c R = SiPh3  
Chiral Acid ee of 2.13 
2.93 2 % 
2.94 10 % 
2.95a 40 % 
2.95b 63 % 
2.95c 74 % 
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We then sought to examine the diastereoselectivity of the C-ring formation.  
Formation of only the desired diastereomer ----- was observed when N-Tse ----- was 
subjected to the cyclization conditions (Scheme 2.29).  The transformation was clean 
rest of the mass balance was attributed to some degree of decomposition and none of the 
undesired bis-epi  diasteromer 2.96 was observed by NMR.  In the absence of the N-Tse 
protecting group, a mixture of diasteromers 2.89 and 2.92 with a dr of 1:2 in favor of the 
undesired cyclization product 2.92 was observed. 
 
Scheme 2.29 
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  The dependence of the diastereoselective formation of the C-ring on the presence 
or absence of the Tse protecting group can be attributed to the lower energy, major 
conformer of the N-acyliminium intermediate 2.86 and 2.98 (Scheme 2.30).  
Particularly, the s-cis and s-trans conformers formed upon rotation of the C(7)-C(8) 
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single bond plays a key role whether C(4)-H and C(8)-H ends up cis or trans in the 
monocyclized adduct (cf. 2.88).  With the Tse group present, s-trans 2.86 conformer  is 
favored over the s-cis 2.86 conformer due to steric interactions between the Tse and the 
bromopyrrole moieties in the latter.  This leads to a transition state arrangement ---- 
leading to the desired trans-C(4)-H-C(8)-H diasteromer 2.88.  On the other hand, the 
absence of the Tse in 2.98 allowed s-cis 2.98 conformer to be dominant based on the 
observed results leading to the wrong diastereomer 2.92 (Scheme 2.29) as the major 
product. 
 
Scheme 2.30 
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2.6 Final Cyclization Investigations: Completion of Synthesis 
At this point, all that remains to be done is to form the final B-ring.  As the 
pyrrole N(12) failed to cyclize onto the conjugated N-acyliminium intermediate, we 
sought different strategies.  Since this failure was partly attributed to ineffective 
conjugation of the C(6)-C(7) olefin with the N-acyliminium, we envisioned that 
electrophilic activation of this double bond should promote nucleophilic trapping with 
the pyrrole nitrogen.  After screening different sources of electrophilic halogens or 
oxidants (e.g. NBS, NIS, mCPBA) to form activated intermediate 2.89,  we found that 
the C(6)-C(7) olefin was of inferior nucleophilicity compared to the bromopyrrole 
moiety (Scheme 2.31).  In this case the electrophiles preferred to react with the electron-
rich pyrrole, which was further activated by the C(13)-Br towards electrophilic aromatic 
substitution. Alternatively, we also examined the possibility of performing a base-
promoted hydroamination.   While this approach worked with the alkyne precursor prior 
to C-ring formation, in this case screening of bases proved to be a dead end.  In an 
attempt to relieve strain in the D ring of N-acyliminium intermediate derived from 2.88, 
we envisioned that a base should be able to deprotonate the C(5)-OH to induce a 
transient opening of the D-ring revealing a cyclopentanone that is amenable to an aza-
Michael addition.  This regenerates the C(5) carbonyl  ready for D-ring reclosure by 
nucleophilic attack of N(1)-Me. 
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Scheme 2.31 
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Interestingly, several previous syntheses of agelastatin A requiring late-stage B 
ring closure, proceeded via an enone intermediate bolstering this idea further.4a,4h,4i,4k,4o,4q   
The monocyclized adduct 2.88, however, was quite stable to bases and did not yield any 
desired product 2.101 even at elevated temperatures.  We reasoned that the protecting 
group on N(3) was the key steric issue, preventing D-ring opening.  To this end, the Tse 
protecting group on the urea nitrogen was removed to enable greater conformational 
mobility and facilitate D-ring cleavage.  NaHMDS was found to be the best base for 
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deprotection over KHMDS, which gave 10% lower yield (Scheme 2.32).  After much 
experimentation, we serendipitously found that bicyclic intermediate 25 is readily 
converted to agelastatin A 2.1 on silica gel33 pretreated with triethylamine under solvent-
free conditions with mild heating.  4,5-Bis-epi-agelastatin A 2.102 was observed as a 
byproduct of the cyclization, presumably arising from a retro-Nazarov or a retro-5-exo-
trig ring-opening followed by recyclization.  This silica gel-promoted cyclization was 
scaled up with the use of toluene to assist the uniform heating of silica gel.  Inspection of 
the toluene layer reveals that there is no dissolution of precursor and the transformation 
happens through an apparent templating effect on the surface of the gel.  The precursor 
2.89 is adsorbed on regular TLC plates (pretreated by immersion in 10% triethylamine in 
hexanes) as thick bands and eluted with 10% methanol in dichloromethane for a more 
uniform distribution on the silica gel surface.   When methanol is used as solvent, the 
precursor is desorbed from the silica gel and no reaction happens.  Also, without 
triethylamine pretreatment of the silica gel used, the starting material cleaves into two 
fragments occurring probably through a retro-Nazarov or retro-5-exo-trig followed by 
hydrolysis (cf 2.103 and 2.104.) 
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Scheme 2.32 
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Attempted cyclization with alternative substrates revealed that removal of the 
Tse group and the presence of unprotected C5-OH and the bromine at C13 of the pyrrole 
ring of 2.89 were essential for successful cyclization.  The importance of the bromine in 
this cyclization event is quite remarkable since all agelastatin have at least this bromine 
in the pyrrole.  Another interesting aspect is that in the presence of the Tse, the reaction 
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delivers  2.103 and 2.104, instead of intramolecular cyclization.  This points out to the 
importance of an unprotected N(3)-H and C(5)-OH for H-bonding.  Based on these 
experiments, we propose that extensive H-bonding is involved in the transition state 
enabling D-ring opening to give 2.105 followed by an aza-Michael to form the final B-
ring giving 2.106, with concomitant reclosure of the methyl urea to give agelastatin A 
(Scheme 2.32). 
2.7 Conclusions 
In summary, a concise total synthesis of agelastatin A 2.1 via two sequential, 
potentially biomimetic cyclizations was completed. The described sequential assembly 
of the C and B rings provides evidence for the proposed reactivity of a linear alkenyl 
imidazolone pyrrole leading to the agelastatins and complements other approaches to 
agelastatin involving initial B ring followed by C ring formation.4s C-ring formation, 
which sets three contiguous centers in a highly diastereoselective fashion, was 
accompanied by an intense red color that we propose involves a !"!* transition 
between the HOMO and LUMO of N-acyliminium intermediate 2.86 which is supported 
by TD-DFT calculations. The final B-ring closure was uniquely successful and occurs on 
the surface of the silica gel with uniform heating assistance of toluene. The reaction 
sequence leading from an oxidized keramadine analog (cf. 2.84) through a nagelamide 
J–like intermediate (cf. 2.88) to agelastatin A is a provocative proposal for the 
biosynthesis of the agelastatins that inspired the concise route to the natural product 
reported herein. Further studies of the described strategy, including development of an 
enantioselective version,4s are currently underway.  
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CHAPTER III 
STRUCTURE-ACTIVITY RELATIONSHIP (SAR) AND  
CELLULAR TARGET IDENTIFICATION STUDIES 
 
3.1 Introduction 
The investigation of structure-activity relationships (SARs) of small molecules is 
a central concept in medicinal chemistry. The aim of any SAR Study pertaining to the 
use of natural products as potential drug candidates is to reveal which structural features 
are essential and non-essential to biological activity.  This facilitates not only the 
development of more potent analogs but also provide clues for rational design of a 
biological probe that can be used to identify the cellular receptor of the natural product 
in question.   
Pietra and co-workers10b pioneered the initial SAR data on agelastatin A 2.1. 
They synthesized several semisynthetic derivatives (Figure 3.1) of agelastatin A from 
the material they isolated from Agelas dendromorpha.  Their studies revealed that 
unsubstituted C(5)-OH, N(9)-H and N(3)-H moieties are essential in the B/D transoid 
configuration for high cytotoxicity. Acetylation or methylation of C(5)-OH lead to 20-
fold and 116-fold decrease in potency, respectively.  Methylation of both N(3) and N(9) 
showed 280-fold loss of activity. This however begs the question whether only one of 
these two NHs is essential for bioactivity. Complete reduction of both C(2) ans C(10) 
carbonyls also resulted in loss of activity (33-fold).  The stereochemistry at C(4) and 
C(5) are quite necessary based on a 3-fold loss of potency.  Reductive debromination of 
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the pyrrole C(13) bromine also lead to a significant loss in potency (6-fold).  Although 
this is hypothesized to not necessarily mean the importance of the bromine atom in the 
aromaticity of the pyrrole  but could merely be due to conformational change in the 
tetracycle in its absence. 
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Figure 3.1 Cytotoxicity data (IC50,  µM) against L1210 mouse lymphocytic leukemia 
cells and summary of essential moieties in agelastatin A 
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3.2 Syntheses and Bioactivity of Agelastatin A Derivatives 
We started our SAR studies based on the initial data discussed in the previous 
section. Cellular target identification, as well as biological activity assays were done at 
the laboratories of Prof. Jun O. Liu at Johns Hopkins University in collaboration with 
graduate student Mr. Brandon McClary.  HeLa cells were ultimately chosen to be used 
in the antiproliferation studies since synthetic (±)-agelastatin A was found to have a low 
IC50 of 229 nM with this cancer cell line. All designed derivatives described herein are 
in racemic form.    
Since our synthesis involves sequential biomimetic cyclizations forming the C 
and B rings, we decided to ascertain whether the B-ring of agelastatin A is necessary for 
bioactivity.  Monocyclized intermediates 3.1 and 3.2 (Scheme 3.1) were subjected to 
cytotoxicity assay using HeLa cells and showed that while 3.1 had no inhibition, 3.2 
retained some bioactivity with an IC50 of 2.50 µM.  This suggests that the N(3)-H is 
important for potency and that the uncyclized B-ring is not detrimental to bioactivity.  
To fully mimic the C-D ring in agelastatin A, the C(6)-C(7) olefin needs to be fully 
reduced (Scheme 3.1).  Using Pearlman’s catalyst Pd(OH)2/C, hydrogenation of 3.1 gave  
3.3 with fully reduced C-ring and concomitant removal of the bromine atom.  Using 2-
nitrobenzenesulfonylhydrazide (NBSH), the C(6)-C(7) olefin was chemoselectively 
reduced to give 3.4.  Bioassays, however, indicated that 3.3 showed no inhibition. This 
could mean that the activity of 3.2 might be due to in cellulo B-ring cyclization leading 
to appreciable amounts of the parent compound, agelastatin A,  and thus 3.2 just serves 
as a “pro-drug”.  Following this line of thought, the inactivity of  3.1 could also be due to 
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its inability to undergo B-ring cyclization as observed in our laboratory investigations.  
On the other hand, another difference of 3.3 to 3.2 is the absence of the C(13) bromine 
atom.   Although the bromine is quite remote to the C-D ring junction and its effect on 
the  C/D-ring conformation is minimal, its presence in all agelastatins and the 
importance of a C(13)-bromopyrrole interaction in the active site cannot be dismissed.  
The pending bioassay of 3.4 should be able to address this question. 
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 Agelastatin B (2.2), a C(14)-bromo analog of agelastatin A, was isolated as a 
trimethyl derivative. The absence of biological data on 2.2, as well as the lack of SAR 
studies of the pyrrole C(14) prompted us to investigate substitution at this position.  The 
electron rich nature of the pyrrole allows it to undergo straightforward electrophilic 
halogenation reactions.  N-Bromosuccinimide (NBS) regioselectively brominates the 
C(14) position to give 2.2 (Scheme 3.2).  A mixture of 2:1 THF:water allowed 
dissolution of the starting material and 2,6-di-t-butylpyridine was used to scavenge 
adventitious acid in the reaction mixture.  It also necessitated the addition of NBS as a 
solid instead of addition as a stock solution.  Attempts at using a stock solution lead to 
regioselectivity issues with bromination presumably due to formation of Br2 evidenced 
by slight yellow color change upon dissolution.  Iodination, on the other hand, required 
In(OTf)3 as an activator to produce product 3.5 using N-iodosuccinimide (NIS).  
Iodinated compound 3.5 was then subjected to copper-free Sonogashira cross-coupling 
with bis-alkyne 3.6 to give alkyne derivative 3.7.  The presence of copper iodide in this 
reaction led to inconsistent results.   The distal terminal TMS-alkyne was designed to 
serve as a functional handle for an eventual synthesis of a biotin probe.  Antiproliferation 
assays of 2.2, 3.5, and  3.7  resulted in IC50 values of 5.74 µM,  38.1 µM,  and 1.30 µM, 
respectively.  A clear trend is observed when you consider the steric bulk added, with 
C(14)-iodo-substituted compound 3.5 showing 166-fold loss of activity, followed by 
C(14)-bromo substituted agelastatin B (2.2) showing 25-fold decrease in activity.  It is 
noteworthy, however, that the addition of the linear bis-alkyne at C(14) only showed a 6-
fold loss of activity.  This could point out that the proximal alkyne handle itself does not 
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have steric bulk and allows the molecule to still bind to its cellular target.  This provides 
us with a good lead compound for a cellular probe synthesis. 
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The importance of the C(13)-bromine was not conclusive because its absence, 
while decreasing potency, was also proposed to result in slight changes in the 
conformation of the parent tetracyclic structure.  Thus, we sought substitutions at C(13) 
that are either a bioisostere of bromine or a linker that allows synthesis of a biological 
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probe.  Reduction of the bromopyrrole with hydrogen and Pd(OH)2/C gave 3.8 (Scheme 
3.3).  Copper-free Sonogashira reaction of agelastatin A (2.1) with bis-alkyne 3.6 
yielded 3.9, with a probe linker in place.  Debromoagelastatin A 3.8 lost 17-fold of 
activity based on HeLa cells (IC50 3.81 µM) in contrast to a 6-fold decrease in  L1210 
leukemia cells.  This verifies the importance not necessarily of the presence of a bromine 
atom but a substituent at C(13).   Linker-appended 3.9, on the other hand, was more 
active against HeLa cells than 3.8 at an IC50 of 2.96 µM .  
  
Scheme 3.3 
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More interesting C(13) derivatives are substitutions of  bioisosteres of bromine 
that maintains similar sterics around the pyrrole region.  Methyl derivative 3.10 was 
synthesized using Stille cross-coupling reaction with tetramethyltin (Scheme 3.4).  
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Chloroagelastatin A 3.11 and iodoagelastatin A 3.12 were synthesized using In(OTf)3 
promoted halogenations using N-chlorosuccinimide (NCS) and N-iodosuccinimide 
(NIS).  While biological evaluations of 3.10, 3.11, and 3.12 are pending, these 
derivatives are indeed interesting.  Chloroagelastatin 3.11 not only reduces sterics but 
also lowers the molecular weight farther from the maximum ideal limit of 500g/mol. 
C(13)-Methyl derivative 3.10 on the other hand enhances lipophilicity and solubility. 
      
Scheme 3.4 
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Another possible site of probe attachment is the N(9) position.  As alluded to in 
section 3.1 this position has not been explored.  To access singly-substituted N(9) 
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analog, we took advantage of  the increasing pKa of the acidic protons in the molecule 
(C(5)-OH < N(9)-H < N(3)-H). Deprotonation of the C(5)-OH with LHMDS followed 
by quenching with TMSCl leads to 3.13 (Scheme 3.5). Another equivalent of LHMDS 
deprotonates the N(9)-H and the anion is alkylated with methyl iodide to give 3.14.  
Finally, the transient TMS protecting group is cleaved with tetrabutylammonium 
fluoride (TBAF) to give the desired N(9)-methyl analog 3.15.  The methyl attachment at 
N(9) was verified with HMBC correlatios of the methyl protons with the adjacent 
carbons.   Retention of some bioactivity of 3.15 would lead to an analogous biological 
probe based on N(9) attachment.     
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3.3 Synthesis of a Potent Biotin Conjugate 
Of all the compounds we tested for bioactivity our best lead compound for the 
synthesis of a functional probe for receptor isolation studies was compound 3.7.  The 
ability of this compound to retain activity at 1.30 µM allowed us to extend the linker to 
include a biotin functionality via a Sharpless-Hüisgen cycloaddition with biotin-azide 
3.16 to give the desired biotin conjugate 3.17.  Investigations on the use of 3.17 for pull-
down affinity chromatography experiments are currently underway. 
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3.4 Initial Studies on the Identification of the Cellular Target of Agelastatin A 
To elucidate the cellular mechanism of antitumor activity of agelastatin A (2.1), a 
‘top down approach’ was used to determine the specific effect on three major cellular 
processes: DNA replication, transcription, and translation. The effects of 2.1 on DNA 
synthesis, RNA synthesis, and global protein synthesis were determined using 
incorporation of [3H]-thymidine, [3H]-uridine, and [35S]-methionine as readouts, 
respectively. Treatment of PC3 cells for 1 hour led to a dose-dependent inhibition of 
[3H]-thymidine incorporation into the DNA backbone with an IC50 of 30 nM, and [35S]-
methionine incorporation into newly formed proteins with an IC50 of 80 nM. This meant 
that both DNA synthesis and global protein synthesis is inhibited while RNA synthesis 
was not significantly affected (Figure 3.2). The IC50 value for inhibition of PC3 cell 
proliferation (88 nM) by treatment of agelastatin A for 24 hours correlated well with the 
IC50 value of inhibition of [35S]-methionine incorporation (80 nM). The high correlation 
between these two values led us to believe that agelastatin A is preferentially inhibiting 
protein synthesis. However, the IC50 value for inhibition of [3H]-thymidine incorporation 
(30 nM) is lower than the value for [35S]-methionine incorporation  (80 nM), which 
suggests that DNA synthesis is preferentially inhibited. To consolidate these 
contradicting data, it is quite possible that the synthesis of fast-turnover proteins 
necessary for DNA replication is rapidly inhibited, contributing to a more significant 
effect on DNA synthesis at earlier time points.  This has been commonly observed with 
protein synthesis inhibitors.34 
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Figure 3.2 Effects of agelastatin A on DNA, RNA, and protein synthesis using 
incorporation of  [3H]-thymidine, [3H]-uridine, and [35S]-methionine.  
IC50 values listed next to the corresponding curves. 
 
To confirm this hypothesis of preferential inhibition of translation with agelastatin 
A, cycloheximide (CHX)35, a well-known inhibitor of translation elongation, was 
subjected to the same PC3 cells inhibition experiment (Figure 3.3). Treatment for 1 hour 
results in dose-dependent inhibition of [3H]-thymidine incorporation with an IC50 of 45 
nM, and [35S]-methionine incorporation with an IC50 of 59 nM.   As expected, RNA 
synthesis was not significantly affected.  It is also interesting that similar to agelastatin A, 
CHX also has a lower IC50 value for DNA synthesis. Based on this evidence, it is 
hypothesized that (-)-agelastatin A is also an inhibitor of eukaryotic translation, and DNA 
inhibition effects as commonly observed with translation inhibitors, are likely due to a 
secondary response to the loss of translation. 
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Figure 3.3 Effects of Cycloheximide (CHX) on DNA, RNA, and protein synthesis using 
incorporation of  [3H]-thymidine, [3H]-uridine, and [35S]-methionine.  
IC50 values listed next to the corresponding curves. 
 
To verify that agelastatin A is indeed capable in blocking translation, protein 
synthesis from control RNA templates in rabbit reticulocyte lysate and [35S]-methionine 
was analyzed by SDS-PAGE (Figure 3.4). In this in vitro system, agelastatin A also 
inhibits protein synthesis in a dose-dependent manner verifying that agelastatin A does 
block translation. The difference in the observed IC50 values between cell proliferation 
and translation assays may be attributed to the different drug incubation times and 
intrinsic  sensitivity of the different readouts, as observed with previous work with 
translation inhibitors.35-36  
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Figure 3.4 Dose-dependent inhibition of  [35S]-methionine incorporation by  
agelastatin A in an in vitro translation system. Agelastatin A was added to a  
rabbit reticulocyte lysate cocktail that included luciferase poly(A)  
control mRNA and [35S]-methionine.  
 
The specific step at which agelastatin A interferes with translation remains to be 
determined. A dual luciferase assay using hepatitis C virus (HCV) internal ribosome 
entry site (IRES) was performed to distinguish between the possibilities of agelastatin A 
interfering with the initiation or elongation phase of protein synthesis.  Many viral 
mRNAs and a relatively small number of cellular mRNAs are translated as a result of the 
ribosome attaching to the mRNA at an internal entry site. HCV IRES mediated 
translation initiation does not require the 5’ 7meG-cap structure. By recruiting initiation 
factors directly to the AUG start codon, HCV can bypass the eIF4F complex, which 
contains cap-binding factors eIF4E, and initiation factors eIF4A and eIF4G.37  The dual 
luciferase reporter assay uses bicistronic in vitro reporters with a conventional capped 
firefly luciferase followed by renilla luciferase under the translational control of an IRES 
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element, which are resistant to inhibitors of translation initiation. Transcribed HCV IRES 
dual luciferase reporters were used to perform in vitro translation assays with rabbit 
reticulocyte lysate. AglA dose-dependently inhibited both cap-dependent translation and 
IRES-dependent translation of the mRNAs from both dual luciferase reporters. Treatment 
with CHX at 4 !M resulted   in   nearly   complete   inhibition   of both cap- and HCV 
IRES-dependent translation (Figure 3.5). These results suggest that AglA, like CHX, 
inhibits translation at the elongation phase.  
 
 
 
Figure 3.5  Dual luciferase translation inhibition by agelastatin A using 
HCV IRES dual reporter in an in vitro RRL translation system in the presence of 
different concentrations of agelastatin A and 4 µM CHX. 
 
 Agelastatin A may or may not be binding within the ribosome.  It is possible that 
protein/s associated with translation elongation may in fact be the primary target.  The 
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described agelastatin A C(13)-biotin probe described in the previous section is currently 
being used for affinity chromatography experiments in an effort to isolate the target 
protein of the natural product.   A number of other translation assays is currently being 
conducted to further elucidate the mechanism of action. 
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CHAPTER IV 
SYNTHESES OF 15N-OROIDIN AND 15N-KERAMADINE ANALOG  
FOR BIOSYNTHESIS/ METABIOSYNTHETIC STUDIES* 
 
4.1 Introduction 
The polycyclic pyrrole-2-aminoimidazole alkaloid (P-2-AI) family has received 
much attention from the synthetic organic community1a,1b,38,1c because of their 
challenging molecular structure, dense functionality and potential biological activity. All 
are believed to have been derived from a simple common sponge metabolites; most 
likely oroidin (1.1) and its analogs hymenidin (1.2) and clathrodin (1.3), or a related 
monomeric linear structure keramadine (2.22) (Scheme 4.1)..22,17 Representative of the 
members of this family are the dimeric P-2-AIs sceptrin (4.1),39 ageliferin (1.12),40 
massadine (1.13),41 palau’amine (1.11)42 and axinellamines A and B (1.10a-b),43 and 
higher-order tetrameric P-2-AIs.44 In addition, compact monomeric polycyclic P-2-AIs, 
such as agelastatins A-F (2.1-2.6),10-12 and dibromophakellin45 appear to be derived from 
oxidative intramolecular cyclizations of keramadine (2.22) and oroidin (1.1), 
respectively.  P-2-AIs are of contemporary interest due to their potent biological activity 
                                                
* Part of this chapter is reprinted with permission from [“Synthesis of 7-15N-Oroidin and 
Evaluation of Utility for Biosynthetic Studies of Pyrrole-Imidazole Alkaloids by 
Microscale 1H-15N HSQC and FTMS” by Wang, Y. G.; Morinaka, B. I.; Reyes, J. C. P.; 
Wolff, J. H.; Romo, D.; Molinski, T F. J. Nat. Prod. 2010, 73, 428-434.]  Copyright 
[2010] American Chemical Society (ACS).  
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and intriguing biosyntheses. For example, (–)-agelastatin A (2.1), an antitumor P-2-AI is 
1.5-16 times more active than cisplatin against a range of tumor cell lines6,13, and 
potently inhibits osteopontin, an adhesion glycoprotein transcriptionally regulated by the 
Wnt $-catenin pathway and implicated in tumor progression, dissemination, and 
metastases.15 
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The widely accepted hypothesis for biosynthesis of dimeric and tetrameric P-2-
AIs, involves dimerization of oroidin (1.1) followed by consecutive oxidative 
transformations leading to more densely functionalized, polycyclic alkaloids. In 1982, 
Büchi reported a 'biomimetic' synthesis of the simple P-2-AI, racemic dibromophakellin, 
by oxidative cyclization of 9,10-dihydrooroidin.45a The structure of sceptrin (4.1) is 
highly suggestive of a formal [2+2] cycloaddition of two molecules of hymenidin (1.2) 
to 4.1; however, despite many attempts, Faulkner, Clardy and co-workers were unable to 
achieve photodimerization of 1.2 to 4.139a, suggesting that an alternative mechanism may 
be responsible for the biosynthesis. Recent speculation on the order of biosynthesis of 
4.1 and 1.12 revolves around ionic mechanisms of ring-expansion, supported by the 
demonstrated conversion of 4.1 to 1.12 under thermal conditions,46 or a ring-contraction 
pathway from an ageliferin-type dimer generated by a Diels Alder type cycloaddition of 
two molecules of hymenidin (1.2).17 For example, one speculative hypothesis invokes a 
cycloaddition in the biosynthesis of palau'amine42b and axinellamine, followed by a 
stepwise electrophilic chlorination and ring contraction. However, none of these 
hypotheses have been tested experimentally in live sponges. 
This chapter describes the syntheses of 15N-oroidin (1.1b) and an 15N-keramadine 
analog 2.31a along with optimization of conditions for detection of 15N-incorporation by 
microscale FTMS and 1H-15N HSQC using a 'mock' pulse-labeling experiment with 1.1b 
and natural oroidin (1.1). The limits of detection of these methods are estimated and its 
suitability for use in field incorporation for biosynthetic studies of complex P-2-AIs with 
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living sponges is determined. This can be useful to answer biosynthetic questions of the 
biosynthesis of P-2-AIs by sponges in the genera Agelas, Stylissa and Ptilocaulis. 
4.2 Synthesis of 15N-Oroidin 
Our retrosynthetic analysis (Scheme 4.2) of 15N-oroidin starts with cleavage of 
the amide bond to yield the known 4,5-dibromo-2-trichloroacetylpyrrole 4.2,20b,c readily 
prepared by bromination of commercially available 2-trichloroacetylpyrrole, and 2-
azidoimidazole allylic amine 4.3, which could be accessed ultimately from the natural 
synthon urocanic acid 4.6.  The amino group at the 2-position of the imidazole ring will 
be introduced via a lithiation/azidation sequence, while the 15N label will be introduced 
by Gabriel synthesis employing the potassium salt of commercially available 15N-
phthalimide 4.4. 
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The synthesis commenced with a Fisher esterification of urocanic acid with 
anhydrous methanolic HCl and subsequent protection gave the known N-trityl imidazole 
derivative 4.7 (Scheme 4.3).  Reduction of ester 4.7 with DIBAL-H afforded the 
corresponding alcohol in excellent yield.  Initial attempts to execute a direct azidation of 
alcohol 11 at the 2-imidazole position with the unprotected alcohol using known 
procedures gave none of the desired azido product.  Instead, the product obtained was 
tentatively assigned the structure of a triazene-imidazole derivative based on 1H NMR 
and mass spectrometric analysis. When the TBS protected alcohol 4.8 was subjected to 
the previously employed conditions for azido-transfer, the corresponding azide was 
obtained in excellent yield.  Deprotection with TBAF afforded alcohol 4.9, which was 
then subjected to mesylation (MsCl, Et3N).  Without purification, the mesylate was 
treated with the potassium salt of 15N-phthalimide (>98% atom 15N) to provide the 15N-
labeled pthalimide 4.10.  Cleavage of phthalimide 4.10 with NH2NH2 (hydrazine) 
furnished the requisite 15N-allylic amine which was acylated with 4,5-dibromo-2-
trichloroacetylpyrrole (4.2) to provide 15N-pyrrolecarboxamide 4.11 in good overall 
yield.  Removal of the trityl group from 4.11 with anhydrous methanolic HCl, generated 
in situ from acetyl chloride and MeOH, afforded the corresponding 2-azido imidazole 
that was hydrogenated in the presence of Lindlar's catalyst to provide 7-15N-oroidin 
(1.1b, >98% atom 15N). 
The 1H, 13C and 15N NMR spectra and mass spectra were fully consistent with the 
structure and location of the 15N label as depicted.  The FTMS of natural oroidin (1.1), 
Figure 4.1) shows the expected 1:2:1 pattern for the pseudomolecular ion [M+H]+ 
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associated with the 79Br and 81Br isotopomers (m/z 387.93990, !mmu = –0.41 mmu). 
The FTMS spectrum of 7-15N-oroidin (1.1b) (Figure 4.1b) shows the same ion pattern, 
only the distribution is increased by 1 amu (m/z 388.93719, !mmu = –0.16).  Less than 
2% of the 14N isotopomer was detected which is consistent with the reported purity of 
the 15N pthalimide (>98% atom 15N) employed in the synthesis. 
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Figure 4.1 MALDI FTMS (7T) expansions of the pseudomolecular ion [M+H]+ of 
oroidin for (a) natural 1.1 (C11H12Br214N5O) and (b) 7-15N-oroidin (1.1b), 
C11H12Br214N415NO, >98% atom 15N. Mass accuracy = 1ppm. 
 
4.3 Synthesis of 15N-Keramadine Analog  
Our retrosynthetic analysis of 15N-keramadine analog 2.31a starts with a Lindlar 
reduction to introduce the Z-configured olefin with concomitant reduction of the azide 
group reveling the 2-aminoimidazole moiety (Scheme 4.4).  Cleavage of the amide bond 
then reveals two fragments 5-bromo-2-thrichloroacetylpyrrole 4.2 and propargylic amine 
derived from 4.13.  The 15N label will be introduced via a Gabriel synthesis employing 
the potassium salt of commercially available 15N-phthalimide 4.4 and propargyl bromide 
(a) 
(b) 
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4.14.  The alkyne moiety will then be coupled with the imidazole 4.15 through a 
Sonogashira cross coupling reaction. 
 
Scheme 4.4 
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 Protection of the nitrogen in 4.15, distal to the iodine, yields an appropriately 
protected N-benzenesulfonamide 4.16  (Scheme 4.5).  This is then coupled to the 
substitution product 4.17 of propargyl bromide 4.14 and 15N-phthalimide potassium salt 
4.4 through a Sonogashira cross coupling reaction yielding 4.18.  The N-Me is then 
introduced to the imidazole ring by formation of an N-Me imidazolium salt formed in 
situ by reaction with BF4OMe3 (methyl Meerwein salt).  In the same pot, addition of 
methanol leads to the removal of the benzenesulfonyl group through methanolysis 
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providing 4.13. The final guanidine nitrogen will then be introduced through a lithiation-
azidation sequence followed by phthalimide cleavage to reveal propargyl amine 4.20 
that will be coupled to 5-bromo-2trichloroacetylpyrrole 4.2a to yield 4.12.  A final 
Lindlar reduction will then deliver the desired 15N-keramadine analog 2.31a with the Z-
configured olefin and the 2-aminoimidazole moiety in place.    
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 Our interest in the synthesis of 15N-keramadine analog 2.31a stems from our 
biosynthetic proposal that it is the ultimate precursor of the agelastatin subfamily of P-2-
AI alkaloids.  The 15N label will allow us to follow its conversion not only to 
agelastatatins but quite possibly to other P-2-AIs, isolated or otherwise.  The next section 
details our planned approach on how to ascertain 15N incorporation via mass 
spectrometry and NMR spectroscopy.  
4.4 Evaluation of the Utility of 15N-Oroidin for Biosynthetic Studies by HSQC and 
FTMS 
Two general methods are available for measuring incorporation of the stable 
isotope 15N into natural products by pulse labeling – mass spectrometry and NMR 
spectroscopy.  In both techniques, the level of isotopic enrichment from de novo 
biosynthesis of derived P-2-AIs must exceed the background 15N present in P-2-AIs 
already present in the sponge and, for MS in particular, any 15N background for other 
nitrogen atoms in the molecule.  As a stable isotope label, 15N is easier to detect and 
preferable to 13C because the natural abundance of the heavier to lighter isotope for N 
(~0.3%) is only about 1/4 of C (~1.1%).  Ideally for 15N incorporation experiments, mass 
spectrometry should differentiate the contributions to the M+1 peak from 15N and 13C,47 a 
task best-suited to Fourier transform MS (FTMS) with exceptionally high resolution (7T 
field, R = 240,000) that should be capable of resolving the nominal M+1 peak of the 
pseudomolecular ion into individual isotopomer contributions from species containing 
one 13C or one 15N.  Baseline separation of the isotopomers was readily achieved by 
MALDI FTMS (Figure 4.2), allowing quantitation of the 15N isotopomer peak. For 
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oroidin (1.1), the critical difference in the mass of 12C-15N containing ions versus the 
heavier 13C-14N isotopomer amounts to only 0.00632 amu, a baseline separation not 
readily achievable by high-resolution mass spectrometers with conventional analyzers 
(e.g. double sector, TOF).  
Quantitation of the 15N isotopomer can be made from integration of ion current 
intensities of the [M+1] components, 15N-12C and 14N-13C (Figure 4.2). Assuming the 13C 
abundance in natural and synthetic 15N-labeled oroidin are identical, the 13C peak 
intensity may be used as the denominator in the ratio h (Equation 4.1), where hN and hC 
are the respective measured peak heights of the 15N-12C and 14N-13C component ions.  
 
h = hN/hC     (Eqn 4.1) 
 
Consequently, h can be used to reflect small changes in the 15N content.48 From 
the ion current peak heights measured in the FTMS spectrum of natural oroidin (1.1), h 
was found to be 0.1487±0.0175.  A prepared 'mock' labeled sample ('Mix1'), consisting 
of a 1.5:0.0075 mixture of oroidin (1.1): 7-15N-oroidin (1.1b), showed an enhanced h of 
0.1881±0.0135 corresponding to a ~4% 15N enrichment.  A second sample ('Mix2', 
1:0.100, 1.1:1.1b) gave h = 1.024±0.0369, corresponding to ~88% 15N enrichment.  We 
estimate that the limit of detection (LOD, ±3 %) for 15N incorporation corresponds to an 
increase in intensity, !h ~5.2%. Given that natural abundance of 15N is approximately 
0.3% atom, this would amount to observation of as little as 10.4 parts per thousand of 
15N incorporation per N atom of oroidin (1.1) by de novo synthesis.  Detection of this 
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small amount will, of course, be made more difficult by the presence of unlabeled 
oroidin (1.1) within the sponge.  
 
   
h h h
(a) (b) (c)
 
 
Figure 4.2 MALDI FTMS (7T) expansions of m/z and peak height, h, for the 'M+1' peak 
of the pseudomolecular ions of oroidin (C11H11Br2N5O). Mass accuracy = 1 ppm (R = 
240,000). (a) natural 1.1. (b) 1.1 + 1.1b (0.04 mol equiv). (c) 1.1 + 1.1b (0.10 mol 
equiv). Peak assignments of [M+H]+ in (c): m/z 388.94372, 12C1013CH12Br2N5O+;  
m/z 388.93739; 12C11H12Br2N415NO+. The unrelated peak at m/z 388.9305  
(indicated with an ‘*’) is tentatively assigned to some loss of H from the dominant 
79Br/81Br isotopomer, C11H1079Br81BrN5O+ ([M]+, !mmu = –0.5) 
 
The disadvantage of analysis of 15N-content in oroidin and other P-2-AIs by MS 
is the presence of at least five N atoms, each contributing to the intensity of 15N-12C 
component of the M+1 peak. Consequently, it may be expected the actual LOD by 
FTMS will be higher. 
Direct detection of 15N incorporation by 15N NMR spectroscopy is impractical 
due to low natural abundance and severely compromised sensitivity of this I=" nucleus 
which possesses a low-magnitude, negative magnetogyric ratio (& = – 4.31726570 MHz 
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T–1).49 Conveniently, 1H-15N HSQC circumvents most of these problems by indirect 
detection of bonded 1H-15N couplets through magnetization transfer from 15N and 
observation of the more sensitive 1H nucleus. Because four of the five N atoms in 
oroidin (1.1) are bonded to H, 2D 1H-15N HSQC can provide bond-specific information 
about fractional enrichment at an individual N atom in oroidin and, by extension, more 
complex P-2-AIs by measurement of the 1H-15N couplet intensity. The intensity of cross 
peaks in the 2D 1H-15N HSQC spectrum of oroidin will vary for each N-H couplet 
depending on efficiency of magnetization transfer that largely depends upon the 
magnitude of the 1JNH scalar coupling constant. Nevertheless, the intensity of each 
crosspeak will scale linearly as a function of 15N abundance.   
When put to practice, it is easier and more meaningful to measure 15N enrichment 
from the 1D projections of 2D HSQC spectra or – best of all – from the 1D version of 
the HSQC experiment where evolution of the F1 dimension (15N chemical shift) is 
eliminated and acquisition time is devoted to improving S/N in the detected dimension 
F2 (1H chemical shift).  We define here !I as the difference of cross peak intensity, I, of 
the 15N-labeled N-H couplet of interest (in this case, the NH(C=O) signal of 1.1b) in a 
sample of oroidin (1.1), spiked with a known amount of 7-15N-oroidin (1.1b), compared 
to the intensity, I0, of oroidin recorded under the same conditions (Equation 4.2).  The 
values of I are normalized to the intensity of the pyrrole N-H couplet of oroidin (Ip = 
1.00) in each experiment. 
∆I  =  (I – I0)/I0     (Eqn. 4.2) 
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We elected to use the pyrrole N-H couplet of oroidin (1.1) (#H = 13.14, s; 
#N169.1) as the control because of its ready assignment from 1H-15N HMBC, lack of 
tautomerism, and likely origination in a different biosynthetic pathway unaffected by 
biosynthetic incorporation of 15N into the amino-imidazole fragment. The exquisite 
mass-sensitivity of the triple-tuned [13C,15N]1H 1.7 mm 600 MHz microcryoprobe was 
used to full advantage in this work for characterization of the 15N content of oroidin 
samples. This low-volume, high-mass sensitivity cryoprobe allowed measurements of 
samples of only ~1.5 mg in 30 µL (acquisition times, ~4 h).  Figure 4.3 shows the 2D 
1H-15N HSQC experiment for oroidin (1.1) with respective N assignments (also, see the 
Experimental for accurate #'s). A single dominant cross peak was observed in the 2D 1H-
15N HSQC of 7-15N-oroidin (1.1b) (not shown), confirming the location of the 15N label 
at the amide group N-H (#H = 8.75, t, 3JHH = 6.0 Hz, H7; #N = 107.8, '7), as expected.  
Figure 4.4a-c shows 1D 1H-15N HSQC experiments of oroidin (1.1) spiked with 
different amounts of 7-15N-oroidin (1.1b) and the integrals of each N-H couplet, 
normalized to the N1-pyrrole couplet are reported in Table 4.1 (note that the integrals are 
not exactly proportional to the stoichiometric ratios of attached H's).  As predicted, the 
value of !I increases linearly with the amount of added 7-15N-oroidin (1.1b) and the 
slope of this 'standards addition' linear regression (Figure 4.5) gives the proportionality 
constant c = 0.34 for !I per µg of added 1.1b.   
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Figure 4.3 2D 1H-15N HSQC (600 MHz, 1:1 DMSO-d6/benzene-d6) of natural oroidin 
(1.1, depicted tautomer is arbitrary). N locants are labeled following the numbering 
scheme of Assman and Köck50. ns = 16, T2, T1 = 2K x 256; F2, F1 = 2K x 1K; d1 =1.5s 
 
Table 4.1 Integrals from 1H-15N 1D HSQC of natural oroidin (1.1, 1.5 mg/ 30 µL)  
and 1.1 'spiked ' with 1.1b.  Integrals of H-N couplets corresponding to  
N-12, N-14 and N-16 vary due to tautomerism. 
 
Aliquot !g 
1.1b 
N(12) N(1) N(14) N(7) N(16) 
0.0 1.26 1.00 1.05 2.17 2.14 
2.5 1.03 1.00 0.48 2.57 2.23 
5.0 1.65 1.00 1.18 3.83 2.55 
10.0 0.63 1.00 0.00 5.74 3.02 
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Figure 4.4  1D 1H-15N HSQC experiments (1H #, 1.7 mm microcryoprobe, 600 MHz) of 
1.1 with N-H assignments. Labels indicate N atom assignments made from a separate 
1H-15N HMBC experiment (not shown). (a) 1500 µg of 1.1, no added [15N]-1.1b. (b) 
1500 µg 1.1 + 10 µg 1.1b. (c) 1500 µg 1.1 + 5.0 µg 1.1b. (d) 1500 µg 1.1 + 2.5 µg.  
Relaxation delay, d1 = 1.50 s, optimized for 1JN-H = 90 Hz; 1H #/2 pulse = 12 µS, 15N #/2 
pulse = 34 µS; NA = 6K; dummy scans = 16; NI = 1; T2 = F2= 8K points (no zero fill). 
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 Constant c will be useful for estimation of absolute %N incorporations in P-2-
AIs labeled during in-field incorporation experiments of secondary metabolism within 
living sponges.  Although it is advisable to measure the relative HSQC intensities of 
pyrrole N-H couplet and NH(C=O) couplets of the specific P-2-AI in question, it may be 
reasonably expected that the magnetic properties of these couplets in more complex P-2-
AIs are comparable to those of oroidn (1.1). We estimate the limit of detection (LOD) 
for 15N enrichment by HSQC in 1.1 to be approximately 1.5 parts per thousand (based on 
±3 SD).  This is more sensitive than the LOD of 15N-enrichment by FTMS, the reason 
being HSQC detection of couplet 15N-1H at each N atom and eliminates background 
'dilution' by other 15N's, however the precision is inferior to FTMS replicate 
measurements.  
0
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Figure 4.5 Linear regression of 1H-15N HSQC NH(C=O) cross-peak integral ratio, (I–
I0)/I0, of 'mock' pulse labeling experiments with natural abundance 1.1 (1500 µg, I0) 
spiked with measured aliquots of 1.1b (µg, 'x-scale').  Observed I' values for the  
NH-C=O 1H-15N couplet are normalized to the intensity of the pyrrole N-H cross peak,  
I0 = 1.00 (I or I0 = I'/Ip). Error bars are ± SD. 
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4.5 Biosynthetic Feeding Experiments and ‘Metabiosynthetic’ Studies 
Two phases of P-2-AI biosynthesis can be considered: the assembly of oroidin 
(1.1), and downstream conversion of the latter to monomeric and more complex dimeric 
P-2-AIs.  Despite much speculation, on the biosynthesis of P-2-AIs, only two 
experimental studies in living marine sponges have appeared (Scheme 4.6). Kerr and co-
workers found that cultured cells of Teichaxinella morchella (Styllisa caribica) produced 
14C-labeled stevensine (4.24)51 – the simplest monomeric P-2-AI related to oroidin (---)– 
upon exposure to U-14C-labeled histidine or C5-14C-ornithine, but not U-14C-arginine 
(Scheme 4.6).52 Incorporation of radiolabeled histidine, ornithine, and proline were 
reported to be 0.026%, 0.024%, and 0.022%, respectively.  Paradoxically, U-14C-
histidine was incorporated into 4.24, but this would require an additional C1 unit from an 
unidentified source to complete the imidazole ring and a non-intuitive substitution of 
NH2 at C-2 of the imidazole ring.  No simple mechanism for this scenario presents itself. 
In 2011, Al Morabit and co-workers have performed similar studies and corroborated 
that proline is indeed the precursor of the acylpyrrole group found in P-2-AIs.  In 
contrast with Kerr and co-workers’ results, histidine incorporation was not observed.  
Their experiments have strongly suggested lysine as the precursor of the 2-
aminoimidazole moiety of oroidin.  Lysine incorporation was measured as 0.031% while 
proline incorporation was slightly lower at 0.025%.  Noticeably lower rates of 
incorporation was observed for radiolabelled arginine and ornithine, which are known 
precursors to proline itself. 
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Scheme 4.7 
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Uncertainties in the origin of oroidin (1.1) are, in theory, addressable by suitable 
15N labeled amino acid incorporation experiments. Unfortunately, low levels of 
radioactivity and percent incorporation, detection of 15N incorporation into P-2-AIs 
using 15N-labeled amino acids may be precluded by the limits of detection. For the above 
reasons, late-stage precursors (e.g. 7-15N-oroidin (1.1b), sceptrin (4.1) and ageliferin 
(1.12) are attractive for mapping the origin of downstream polycyclic P-2-AIs since 
these molecules should be committed intermediates. Measurement of their rates of 
incorporation into P-2-AIs in living sponges of the genera Agelas, Stylissa and 
Ptilocaulis may also provide critical data on the rates of marine alkaloid secondary 
metabolism for which there is no current information.   
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The use of precursors labeled with the spin I=1/2 stable isotope 15N is 
particularly attractive as it provides bond-specific information regarding the flow of 
intermediates in biosynthesis of complex P-2-AIs.  Judicious design and placement of 
the label in 15N-labeled oroidin is important.  Because the primary NH2 group of the 
aminoimidazole group is potentially metabolically labile through deamination reactions, 
we chose to label the amide bond in 15N-oroidin.  Quantitation of 15N incorporation into 
proteins has been made from integration of cross peak volumes of 2D HSQC 
experiments;53 however, in the present work with natural products we show that it is far 
simpler to integrate the corresponding 1D HSQC spectra. 
Finally, although the ratio of sceptrin to ageliferin found in one sample of Agelas 
conifera is ~10:1, the ratios of mono-brominated and dibrominated analogs of sceptrin 
and ageliferin vary slightly from approximately 1:1 ~ 3:4; however, these data do not 
clearly indicate an ordering for a bromination-dimerization sequence in the biosynthesis 
of dimeric P-2-AIs. Propagation of 7-15N-oroidin (1.1b) along the biosynthetic pathway 
to complex P-2-AIs will carry the 15N label through symmetrical and non-symmetrical 
intermediates and detection of residual 15N in strategically chosen N-H bonds in the 
molecule should reveal timing, ordering and molecularity of the C-C bond-forming 
events and the extent of coupling of de novo enzymatic reactions. HPLC analysis of P-2-
AI-containing extracts from A. conifera (Agelasidae), collected in the Florida Keys show 
the presence of sceptrin (2) and ageliferin (3) along with hymenidin (1b), but some 
specimens of Agelas sceptrum collected by us contained sceptrin (2) but were devoid of 
the expected precursors 1.1-1.3.  If 1.1-1.3 are precursors to other P-2-AIs, as is highly 
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probable, this implies that the rates of conversion of 1.1-1.3 to higher-order P-2-AIs are 
highly dependent upon the sponge species, their biosynthetic capacities, and possibly the 
habitats they occupy. 7-15N-Oroidin and 15N-keramadine find great value in systematic 
studies of the time-dependent biosynthesis of P-2-AI natural products by pulse labeling 
in live sponges to answer some of these questions. 
 
Scheme 4.7 
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Our group, in collaboration with the Molinski group have recently described an 
alternative method of probing the biosynthesis of higher order P-2-AIs (Scheme 4.7).54 
Named “metabiosynthesis”, this experiment employs cell-free enzyme extracts  from 
marine sponges Stylissa caribica, Agelas conifera, and Agelas sceptrum.  Freshly 
collected live sponges were converted to cell-free preparations (CFP). The CFPs, which 
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contain active enzymes as an aqueous-organic suspension (0.2 mg protein/mL in 1:9 
CH3CN:0.1M sodium phosphate buffer), converts either  dichloroclathrodin 4.26 and 
15N-oroidin 1.1b to higher order dimeric P-2-AIs benzosceptrin C 4.30 and nagelamide 
H 4.29 (or their chlorinated derivatives, tetrachlorobenzosceptrin C 4.27 and 
tetrachloronagelamide H 4.29 for dichloroclathrodin incubation with CFPs). 
 
Scheme 4.8 
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These two seminal publications from our group and the Molinski group show the 
utility of CFPs of active enzymes can be used to study the biosynthesis of complex P-2-
AIs from oroidin and other proposed precursors.  Our interest in 15N-keramadine is to 
investigate its viability as the biosynthetic precursor to the tetracyclic core of 
agelastatins as we described in our revised biosynthetic proposal detailed in chapter 3.  
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CHAPTER V 
CONCLUSIONS 
 
The pyrrole 2-aminoimidazole (P-2-AI) family of nitrogen rich alkaloids is 
among the most challenging targets in the synthetic community.  With well over one 
hundred and fifty members, new metabolites continue to be isolated from various marine 
sources revealing a myriad of biological activities.  Approaches towards the synthesis of 
P-2-AIs have inspired chemists to develop synthetic strategies aimed at efficiency and 
rapid construction of chemical motifs.  Premised on the isolation of keramadine and 
nagelamide J, a retrobiosynthesis of agelastatin A was devised.  This ultimately led to a 
bioinspired approach to a concise synthesis of the natural product via two sequential, 
potentially biomimetic cyclizations.  A carbinolamide precursor to an N-acyliminium  
mediated cyclization was designed.  Crucial to the success of synthesizing this precursor 
was the use of an N-methoxy amide as a coupling partner to an imidazolone alkynyl 
acetal fragment. While the proposed N-acyliminium biscyclization cascade failed to 
deliver all the rings in the tetracyclic natural product, it efficiently formed the C-ring 
setting three contiguous centers in a highly diastereoselective fashion.  This cyclization 
event was accompanied by an intense red color that we propose involves a !"!* 
transition between the HOMO and LUMO of  an N-acyliminium intermediate which is 
supported by TD-DFT calculations.  Investigations of the diastereoselectivity of this 
transformation revealed the importance of a protecting group at the N3 of the 
imidazolone moiety.  An enantioselective version of this transformation was developed 
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using a chiral BINOL-derived phosphoric acid. The final B-ring closure was uniquely 
successful and occurs on the surface of silica gel with uniform heating assistance of 
toluene. The reaction sequence leading from an oxidized keramadine analog through a 
nagelamide J–like intermediate to agelastatin A is a provocative proposal for the 
biosynthesis of the agelastatins.  The described sequential assembly of the C and B rings 
provides evidence for the proposed reactivity of a linear alkenyl imidazolone pyrrole 
leading to the agelastatins and complements other approaches to agelastatins involving 
initial B ring followed by C ring formation.  
Towards gaining a better understanding of the biosynthesis of monomeric and 
dimeric P-2-AIs, a concise synthesis of 15N-oroidin was devised and a direct method for 
measurement of 15N incorporation by pulse labeling and analysis by 1D 1H-15N HSQC 
NMR and FTMS was developed.  With the use of 15N labeled oroidin being validated 
through the use of active cell-free enzymes for metabiosynthetic studies, the utility of a 
15N-keramadine analog to be converted to agelastatin A and other P-2AIs should shed 
light on the exciting biomachinery of this family of alkalods.  
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General Procedures 
All reactions were performed under a nitrogen atmosphere in oven-dried glassware. 
Dichloromethane was dried by passing through activated molecular sieves or alumina 
(MBraun solvent purification system). Tetrahydrofuran was distilled over sodium and 
benzophenone. Methanol was distilled from Mg turnings.  Triethylamine was distilled 
from calcium hydride.  Other solvents and reagents were used as received from 
commercially available sources.  Deuterated solvents were purchased from either 
Aldrich or Cambridge Isotopes and used as received. 1H NMR and 13C NMR spectra 
were recorded on an 500 MHz spectrometer. 1H NMR chemical shifts are reported as # 
values in ppm relative to residual solvent signals: CDCl3 (7.26 ppm), DMSO-d6 (2.50 
ppm), acetone-d6 (2.05 ppm), CD3OD (3.31 ppm). 1H NMR coupling constants (J) are 
reported in Hertz (Hz) and multiplicity is indicated as follows: s (singlet), d (doublet), t 
(triplet), q (quartet), m (multiplet), br s (broad singlet), dd (doublet of doublet), dt 
(doublet of triplet), dq (doublet of quartet), tq (triplet of quartet), app dt (apparent 
doublet of triplet), app t (apparent triplet), app q (apparent quartet). 13C NMR chemical 
shifts are reported as # values in ppm relative to residual solvent signals: CDCl3 (77.16 
ppm), DMSO-d6 (39.52 ppm), acetone-d6 (29.84 ppm), CD3OD (49.00ppm).  Flash 
column chromatography was performed with 60Å Silica Gel (230-400 mesh) as a 
stationary phase. High resolution mass spectra (ESI or MALDI) were obtained through 
the Center for Chemical Characterization and Analysis (Texas A&M University). Thin 
Layer Chromatography (TLC) was performed using glass-backed silica gel F254 
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(Merck, 250 !m thickness). Visualization of developed plates was performed by 
fluorescence quenching or by staining with ceric ammonium molybdate followed by 
heating. Infrared spectra were obtained as thin film on NaCl plates on a FTIR 
spectrometer.  
 
NH
N OHO2CH2N
MeHN OHO2C
OH
OH
HO2C
+
Me
2.47
2.45
2.46  
 
Acid 2.47.  Imidazolone acid 2.47 was synthesized using a modified literature 
procedure1.  A solid mixture of (±)-tartaric acid 2.45 (100 g, 0.66 mol, 1.0 equiv) and N-
methyl urea 2.45 (55.69 g, 0.73 mol, 1.1 equiv) was added in 6 portions via a scoopula 
(waiting 10-15 min before addition of another portion) to a stirred solution of 440 mL 
concentrated sulfuric acid maintaining the temperature below 45 °C without external 
cooling.  The mixture was then heated to 80 °C and stirred for 3 h at this temperature. 
The dark brown homogeneous reaction mixture was allowed to cool to 23 °C, poured 
onto ice, and the resulting tan solids were filtered.  The solids were washed with cold 
water (200 mL) and acetone (~50mL) to give 50.43 g (54%) of acid 2.47 as a tan 
amorphous solid: Rf = 0.27 (20% MeOH/CH2Cl2); IR (thin film): 3159, 3100, 1638 cm-1; 
1H NMR (500 MHz; DMSO-d6): & 10.85 (br s, 1H), 7.28 (d, J = 2.0 Hz, 1H), 3.28 (s, 
                                                
1 (a) Hilbert, G. E. J. Am. Chem. Soc. 1932, 54, 3413-3419.  (b) Otter, B. A.; Falco, E. A.; Fox, 
J. J. J. Org. Chem. 1968, 33, 3593-3600. 
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3H); 13C NMR (125 MHz; DMSO-d6): & 160.9, 153.8, 118.5, 115.0, 28.5 ppm; HRMS 
(+ESI) Calcd. for C5H7N2O3 [M+H]+: 143.0457, found: 143.0454. 
 
NTse
N OOHC
Me
2.58
NH
N OHO2C
Me
2.47  
 
Aldehyde 2.58.  To a solution of acid 2.47 (10.00 g, 70.4 mmol, 1.0 equiv) in anhydrous 
N,N-dimethylformamide (700 mL) was added K2CO3 (19.45 g, 140.7 mmol, 2.0 equiv).  
After stirring for 10 min, methyl iodide (4.4 mL, 70.4 mmol, 1.0 equiv) was then added 
dropwise and the resulting mixture was stirred for 2 h at 23°C and 1 h at 60 °C. Another 
portion of K2CO3 (19.45 g, 140.7 mmol, 2.0 equiv) was then added followed by addition 
of tosylethyl mesylate (19.59 g, 70.4 mmol, 1.0 equiv). The reaction mixture was stirred 
for 6 h at 60 °C then cooled to 23 °C and concentrated in vacuo.  The residue was 
partitioned between 700 mL EtOAc and 700 mL water.  The layers were separated and 
the organic layer was washed with 700 mL water, dried over Na2SO4 and concentrated in 
vacuo to give the crude ester as a light yellow residue.  To a solution of the crude ester in 
350 mL anhydrous CH2Cl2 at -78 °C was added DIBAl-H (31.4 mL, 175.9 mmol, 2.5 
equiv) dropwise.  The reaction was stirred for 30 min then quenched with 7 mL 
methanol and then a saturated aqueous solution of Rochelle’s salt (350 mL).  The 
mixture was stirred vigorously for 5 h at 23 °C.  The aqueous layer was extracted with 
CH2Cl2 (2 x 350 mL) and the pooled organic layer was dried over Na2SO4 and 
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concentrated in vacuo to give the crude alcohol as a light yellow residue.  To a solution 
of crude alcohol in 350 mL anhydrous CH2Cl2 was added manganese (IV) oxide (34.76 
g, 351.8 mmol, 5 equiv) and stirred vigorously for 8 h at 23 °C.  The mixture was then 
filtered through a pad of Celite and the filtrate was concentrated in vacuo. The residue 
was purified by flash column chromatography (SiO2, 70"80% EtOAc/hexanes) 
providing 18.49 g (85% over 3 steps) of aldehyde 2.58 as a white solid: Rf = 0.19 (70% 
EtOAc/hexanes); IR (thin film): 3103, 2931, 2819, 1709, 1655 cm-1; 1H NMR (500 
MHz; CDCl3): & 9.19 (s, 1H), 7.69 (d, J = 8.0 Hz, 2H), 7.30 (d, J = 8.0 Hz, 2H), 7.16 (s, 
1H), 4.14 (t, J = 6.0 Hz, 2H), 3.55 (t, J = 6.0 Hz, 2H), 3.37 (s, 3H), 2.39 (s, 3H); 13C 
NMR (125 MHz; CDCl3): & 177.2, 152.7, 145.4, 135.9, 130.0 (2C), 127.82, 127.66 
(2C), 123.5, 53.6, 39.1, 29.5, 21.7; HRMS (+ESI) Calcd. for C14H17N2O4S [M+H]+: 
309.0909, found: 309.0906. 
 
NTse
N
OMe
2.58a
NTse
N OOHC
Me
2.58  
 
Alkyne 2.58a.  To a stirred solution of aldehyde 2.58 (5.00 g, 16.2 mmol, 1.0 equiv) in 
48 mL anhydrous MeOH and 85 mL anhydrous CH2Cl2 at -40 °C was added Ohira-
Bestmann reagent 202 (6.23 g, 32.4 mmol, 2.0 equiv) dropwise as an oily liquid  and 1.0 
                                                
2 S. Mueller, B. Liepold, G. J. Roth, H. J. Bestmann, Synlett 1996, 521-522. 
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M NaOMe in MeOH (37.3 mL, 37.3 mmol, 2.3 equiv) dropwise ~5 min later.  The 
reaction was stirred for 60 h at –40 °C then allowed to warm to 23 °C over 1 h before 
addition of 150 mL of a saturated aqueous solution of NaHCO3.  The aqueous layer was 
extracted with CH2Cl2 (2 x 150 mL).  The organic layer was dried over Na2SO4, filtered, 
and concentrated in vacuo. The residue was purified by flash column chromatography 
(SiO2, 70"80% EtOAc/hexanes) to give 2.76 g (56%) of alkyne 2.58a as a light yellow 
solid: Rf = 0.28 (70% EtOAc/hexanes); IR (thin film): 3257, 3124, 2928, 2108, 1685 cm-
1; 1H NMR (500 MHz; CDCl3): & 7.73 (d, J = 8.5 Hz, 2H), 7.34 (d, J = 8.5 Hz, 2H), 
6.54 (s, 1H), 4.02 (t, J = 6.5 Hz, 2H), 3.55 (t, J = 6.5 Hz, 2H), 3.35 (s, 1H), 3.10 (s, 
3H), 2.44 (s, 3H); 13C NMR (125 MHz; CDCl3): & 151.6, 145.1, 136.0, 129.9 (2C), 
127.8 (2C), 117.1, 106.6, 83.8, 71.7, 54.0, 38.8, 28.2, 21.7; HRMS (+ESI) Calcd. for 
C15H17N2O3S [M+H]+: 305.0960, found: 305.0949. 
 
NTse
N
OMe
2.58a 2.59
NTse
N
O
EtO
EtO
Me
 
 
Alkynyl acetal 2.59.  To a suspension of alkyne 2.58a (5.94 g, 19.5 mmol, 1.0 equiv) in 
300 mL triethyl orthoformate was added ZnI2 (6.35 g, 19.5 mmol, 1.0 equiv).  The 
reaction mixture was heated to 110 °C with stirring for 6 h, and then allowed to cool to 
23 °C.  Filtration through a pad of Celite was followed by washing with 100 mL CH2Cl2 
and concentration in vacuo to give a brown residue. The residue was purified by flash 
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column chromatography (SiO2, 20% to 30% acetone/hexanes) to provide 6.65 g (84%) 
of alkynyl acetal 2.59 as a light yellow oil. Rf = 0.35 (40% acetone/hexanes); IR (thin 
film): 3121, 2979, 2928, 2238, 2173, 1685 cm-1; 1H NMR (500 MHz; CDCl3): &  7.69 
(d, J = 8.5 Hz, 2H), 7.30 (d, J = 8.5 Hz, 2H), 6.51 (s, 1H), 5.42 (s, 1H), 3.97 (t, J = 6.5 
Hz, 2H), 3.72 (dq, J = 9.5, 7.0 Hz, 2H), 3.59 (dq, J = 9.5, 7.0 Hz, 2H), 3.50 (t, J = 6.5 
Hz, 2H), 3.06 (s, 3H), 2.40 (s, 3H), 1.22 (t, J = 7.0 Hz, 6H);  13C NMR (125 MHz; 
CDCl3): & 151.6, 145.0, 136.0, 129.9 (2C), 127.8 (2C), 117.0, 106.2, 91.3, 90.7, 73.1, 
61.2 (2C), 54.0, 38.7, 28.2, 21.7, 15.1 (2C); HRMS (+ESI) Calcd. for C20H27N2O5S 
[M+H]+: 407.1641, found: 407.1648. 
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Pyrrole Imidazolone 2.82.  To a solution of alkynyl acetal 2.59 (2.58 g, 6.35 mmol, 1.0 
equiv) and pyrrole carboxamide 2.62 (1.53 g, 6.98 mmol, 1.1 equiv) in 200 mL CH2Cl2 
was added 1.9 g of oven-dried powdered 4Å molecular sieves.  The suspension was then 
cooled to –78 ºC followed by addition of 1.0 M SnCl4 in CH2Cl2 (1.59 mL, 1.59 mmol, 
0.25 equiv).  The reaction mixture was removed from the cold bath and allowed to warm 
to 23 °C and stirred for 2.5 h.  A saturated aqueous solution of NaHCO3 (100 mL) was 
then added and the mixture was stirred vigorously and filtered through a pad of Celite.  
The organic layer was separated and the aqueous layer was extracted with EtOAc (2 x 
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100 mL) and the combined organic layer was dried over Na2SO4, and concentrated in 
vacuo.  The residue was purified by flash column chromatography (SiO2, 0"12% 
acetone/CH2Cl2) to deliver 852 mg (23%) of adduct 2.82 along with recovered starting 
materials (961 mg (37%) alkynyl acetal 2.59 and 988 mg (65%) pyrrole carboxamide 
2.62): Rf = 0.36 (3% acetone/CH2Cl2); IR (thin film): 3236, 3129, 2982, 2934, 2241, 
1697, 1614 cm-1; 1H NMR (500 MHz; acetone-d6): & 7.74 (d, J = 8.5 Hz, 2H), 7.40 (d, J 
= 8.5 Hz, 2H), 7.00 (d, J = 4.0 Hz, 1H), 6.84 (s, 1H), 6.58 (s, 1H), 6.31 (d, J = 4.0 Hz, 
1H), 4.03 (s, 3H), 3.99 (t, J = 6.5 Hz, 2H), 3.74 (dq, J = 9.5, 7.0 Hz, 1H), 3.69 (t, J = 
6.5 Hz, 2H), 3.66 (dq, J = 9.5, 7.0 Hz, 1H), 3.03 (s, 3H), 2.42 (s, 3H), 1.22 (t, J = 7.0 
Hz, 3H); 13C NMR (125 MHz; acetone-d6): & 161.3, 152.2, 145.5, 137.5, 130.4 (2C), 
128.7 (2C), 125.8, 118.5, 118.0, 113.7, 106.5, 106.1, 89.9, 78.0, 74.8, 65.8, 64.4, 54.1, 
39.1, 28.2, 21.5, 15.2; HRMS (+MALDI) Calcd. for C24H28BrN4O6S [M+H]+: 579.0913, 
found: 579.0890. 
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Amide Pyrrole Imidazolone 2.83.  To a solution of pyrrole imidazolone 2.82 (632 mg, 
1.09 mmol, 1.0 equiv) in 60 mL anhydrous THF at -20 °C was added 0.1 M SmI2 in 
THF (21.8 mL, 2.18 mmol, 2.0 equiv).  The reaction was stirred for 20 min and allowed 
to warm to 23 °C.  A 0.1 M solution of Na2S2O3 (100 mL) was then added and the 
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mixture was extracted with EtOAc (3 x 70 mL).  The organic layer was dried over 
Na2SO4, filtered, and concentrated in vacuo leaving a light yellow residue.  The residue 
was purified by flash column chromatography (SiO2, 80"90% EtOAc/hexanes) to 
provide 471 mg (79%) of amide 2.83 as a white solid. Rf = 0.19 (80% EtOAc/hexanes); 
IR (thin film): 3204, 3127, 2976, 2928, 2235, 1682, 1640 cm-1; 1H NMR (500 MHz; 
CD3OD): &  7.71 (d, J = 8.0 Hz, 2H), 7.38 (d, J = 8.0 Hz, 2H), 6.89 (d, J = 4.0 Hz, 1H), 
6.75 (s, 1H), 6.23 (s, 1H), 6.17 (d, J = 4.0 Hz, 1H), 4.02 (t, J = 6.0 Hz, 2H), 3.69 (t, J = 
6.0 Hz, 2H), 3.70-3.63 (m, 2H), 3.08 (s, 3H), 2.42 (s, 3H), 1.23 (t, J = 7.0 Hz, 3H).; 13C 
NMR (125 MHz; CD3OD): & 161.4, 153.0, 146.5, 137.5, 130.8 (2C), 128.9 (2C), 127.7, 
118.4, 114.6, 112.8, 107.7, 105.7, 92.6, 73.1, 71.2, 63.8, 54.3, 39.7, 28.6, 21.6, 15.4; 
HRMS (-ESI) Calcd. for C23H24BrN4O5S [M-H]-: 547.0651, found: 547.0664. 
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(Z)-Alkenyl Pyrrole Imidazolone 2.84.  To a solution of amide 2.83 (144 mg, 0.26 
mmol, 1.0 equiv) in a 1:1 mixture of anhydrous THF and methanol was added Lindlar 
catalyst (278 mg, 0.13 mmol, 0.5 equiv).  Following three evacuations/purge cycles with 
H2, the heterogenous mixture was stirred under 1 atm H2 for 4 h and then filtered 
through a pad of Celite.  The filtrate was concentrated in vacuo yielding a yellow 
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residue. The residue was purified by flash column chromatography (SiO2 pretreated with 
10% Et3N in hexanes then washed with CH2Cl2), 80"90% EtOAc/hexanes) providing 
121 mg (84%) of (Z)-alkene 2.84 as a white solid: Rf = 0.27 (90% EtOAc/hexanes); IR 
(thin film): 3189, 3121, 2925, 1667, 1623 cm-1; 1H NMR (500 MHz; CDCl3/CD3OD): & 
7.70 (d, J = 8.0 Hz, 2H), 7.28 (d, J = 8.0 Hz, 2H), 6.81 (d, J = 4.0 Hz, 1H), 6.50 (s, 1H), 
6.15 (d, J = 4.0 Hz, 1H), 6.01 (d, J = 12.0 Hz, 1H), 6.00 (d, J = 8.0 Hz, 1H)  5.78 (dd, J 
= 12.0, 8.0 Hz, 1H), 4.05-3.96 (m, 2H), 3.66-3.50 (m, 4H), 3.06 (s, 3H), 2.40 (s, 3H), 
1.18 (t, J = 7.0 Hz, 3H); 13C NMR (125 MHz; CDCl3/CD3OD): & 160.8, 152.8, 145.6, 
136.1, 130.2 (2C), 129.3, 128.3 (2C), 126.8, 119.7, 116.7, 113.9, 112.3, 112.0, 104.9, 
76.2, 63.0, 54.2, 38.7, 27.6, 21.7, 15.3; HRMS (+ESI) Calcd. for C23H28BrN4O5S 
[M+H]+: 551.0964, found: 551.0945. 
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Monocyclized adduct 2.88.  To a suspension of cyclization precursor 2.84 (51.0 mg, 
92.5 µmol, 1.0 equiv) in 4 mL CH2Cl2 at -78 ºC was added trifluoroacetic acid (212 µL, 
2.77 mmol, 30.0 equiv).  The reaction was immediately warmed to –30 ºC and stirred for 
5 min to give a dark red solution.  A 10 mL saturated aqueous solution of NaHCO3 was 
then added and the mixture was removed from the cold bath and allowed to warm to 23 
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oC while stirring vigorously.  The crude mixture was extracted with EtOAc  (3 x 10 mL) 
and the combined organic layers were dried over Na2SO4, filtered, and concentrated in 
vacuo to give a yellow residue. The residue was purified by flash column 
chromatography (SiO2, 80"85% EtOAc/hexanes) providing 38.5 mg (80%) of cyclized 
adduct 2.88 as an off-white solid: Rf = 0.20 (80% EtOAc/hexanes); IR (thin film): 3207, 
3067, 2928, 1682, 1626 cm-1; 1H NMR (500 MHz; CD3OD): &  7.80 (d, J = 8.0 Hz, 
2H), 7.33 (d, J = 8.0 Hz, 2H), 6.79 (d, J = 4.0 Hz, 1H), 6.17 (d, J = 4.0 Hz, 1H), 6.16 
(dd, J = 6.0, 2.0 Hz, 1H), 5.91 (dd, J = 6.0, 2.0 Hz, 1H), 4.74 (app q, J = 2.0 Hz, 1H), 
3.84-3.73 (m, 2H), 3.65 (d, J = 2.0 Hz, 1H), 3.63-3.51 (m, 2H), 2.78 (s, 3H), 2.40 (s, 
3H);  13C NMR (125 MHz; CD3OD): & 161.7, 158.7, 146.5, 137.3, 134.7, 133.5, 131.0 
(2C), 129.2 (2C), 128.3, 113.7, 112.6, 104.7, 98.2, 74.2, 61.1, 54.4, 38.3, 25.4, 21.6; 
HRMS (-ESI) Calcd. for C21H22BrN4O5S [M-H]-: 521.0494, found: 521.0470. 
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pre-Agelastatin A 2.89.  To a solution of cyclized adduct 2.88 (38.5 mg, 0.07 mmol, 
1.0 equiv) in anhydrous THF (5 mL) was added 1.0 M KHMDS in THF (221 µL, 0.22 
mmol, 3.0 equiv). The mixture was stirred for 0.5 h at 60 °C and was allowed to cool to 
23 °C.  A saturated aqueous solution of NH4Cl (10 mL) was then added followed by 
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extraction with EtOAc (3 x 10 mL). The combined organic layers were dried over 
Na2SO4, filtered, and concentrated in vacuo to give a yellow residue. The residue was 
purified by flash column chromatography (SiO2, EtOAc) providing 15.6 mg (62%) of 
pre-agelastatin A 2.88 as a white solid: Rf = 0.14 (EtOAc); IR (thin film): 3287, 2925, 
1682, 1632 cm-1; 1H NMR (500 MHz; CD3OD): &  6.79 (d, J = 4.0 Hz, 1H), 6.20 (dd, J 
= 6.0, 2.0 Hz, 1H), 6.13 (d, J = 4.0 Hz, 1H), 5.99 (dd, J = 6.0, 2.0 Hz, 1H), 4.66 (app q, 
J = 2.0 Hz, 1H), 3.67 (d, J = 2.0 Hz, 1H), 2.79 (s, 3H);  13C NMR (125 MHz; CD3OD): 
& 162.2, 160.7, 134.5, 133.8, 128.2, 113.9, 112.5, 104.8, 100.5, 70.0, 63.9, 25.1; HRMS 
(+ESI) Calcd. for C12H14BrN4O3 [M+H]+: 341.0249, found: 341.0239. 
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Agelastatin A and 4,5-bis-epi-agelastatin A. Pre-Agelastatin A (2.89) (3.8 mg, 
11.1µmol) was loaded onto four 10 cm x 5 cm TLC plates (pre-treated with 10% Et3N in 
hexanes and dried extensively with a heat gun).  The plates were then eluted with 10% 
MeOH in CH2Cl2 to ensure uniform adsorption onto silica gel particles, dried using a 
heat gun for 1 min, then heated with a hot plate (surface temperature 45 ºC) for 50 
minutes. (Note: Monitoring of the reaction was done by scraping off a small amount of 
silica gel and adding a drop of methanol followed by TLC analysis).  The product band 
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was then scraped off from the entire TLC plate and eluted with 30% MeOH in CH2Cl2 
(15mL).  The organics were concentrated in vacuo and purified by preparative TLC 
eluting and washing with 10% MeOH in CH2Cl2 to give 2.6 mg (68%) agelastatin A 
(2.1) as a white solid and 0.5 mg (13%) 4,5-bis-epi-agelastatin A (2.102) as a thin film.  
Agelastatin A (2.1); Rf = 0.17 (10% methanol/CH2Cl2); IR (thin film): 3257, 2916, 2851, 
1652, 1555 cm-1; 1H NMR (500 MHz; CD3OD): & 6.91 (d, J = 4.0 Hz, 1H), 6.33 (d, J = 
4.0 Hz, 1H), 4.60 (app dt, J = 12.0, 6.0 Hz, 1H), 4.09 (d, J = 5.5 Hz, 1H), 3.88 (s, 1H), 
2.81 (s, 3H), 2.65 (dd, J = 13.0, 6.5 Hz, 1H), 2.10 (app t, J = 13.0 Hz, 1H); 13C NMR 
(125 MHz; CD3OD): & 161.4, 161.1, 124.1, 116.0, 113.8, 107.3, 95.7, 67.4, 62.2, 54.4, 
40.0, 24.2; HRMS (+ESI) Calcd. for C12H14BrN4O3 [M+H]+: 341.0249, found: 
341.0257. 
 
4,5-bis-epi-agelastatin A (2.102); Rf = 0.20 (10% methanol/CH2Cl2); IR (thin film): 
3292, 2922, 2848, 1691, 1555 cm-1; 1H NMR (500 MHz; CD3OD): & 6.90 (d, J = 4.0 
Hz, 1H), 6.33 (d, J = 4.0 Hz, 1H), 5.00 (ddd, J = 10.5, 7.0, 5.0 Hz, 1H), 4.42 (app t, J = 
5.5 Hz, 1H), 4.01 (d, J = 6.0 Hz, 1H), 2.73 (s, 3H), 2.52 (dd, J = 13.0, 7.0 Hz, 1H), 2.26 
(dd, J = 13.0, 10.5 Hz, 1H); HRMS (+ESI) Calcd. for C12H14BrN4O3 [M+H]+: 341.0249, 
found: 341.0236 
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Debromo Dihydro Pre-Agelastatin A (3.3).  To a solution of cyclized adduct 3.2 (3.1 
mg, 0.009 mmol, 1.0 equiv) in 2:1 THF:H2O (0.75 mL) was added triethylamine (7 !L, 
0.05 mmol, 5.5 equiv) and 20 wt.% Pd(OH)2 on carbon (1.3 mg, 0.002 mmol, 0.2 equiv).  
The reaction was purged with H2 stirred under this atmosphere for 4h. The reaction 
mixture was then filtered through a celite plug washing with 20% methanol in DCM.  
The filtrate was concentrated in vacuo to give a white residue. The residue was purified 
by preparative TLC eluting and washing with 10% MeOH in CH2Cl2 to give 2.1 mg 
(87%) of 3.3 as a white solid: Rf = 0.32 (10% MeOH in DCM); IR (thin film): 3281, 
2928, 1676, 1626 cm-1; 1H NMR (500 MHz; CD3OD): $  6.91 (dd, J = 2.5, 1.5 Hz, 1H), 
6.87 (dd, J = 3.5, 1.5 Hz, 1H), 6.16 (dd, J = 3.5, 2.5 Hz, 1H), 3.95 (td, J = 6.0, 3.0 Hz, 
1H), 3.59 (d, J = 3.5 Hz, 1H), 2.77 (s, 3H), 2.14 (dt, J = 13.5, 7.5 Hz, 1H), 2.03 (dt, J = 
13.5, 6.0 Hz, 1H), 1.93-1.99 (m, 1H), 1.86-1.93 (m, 1H); 13C NMR (125 MHz; CD3OD): 
& 164.0, 161.4, 126.6, 123.0, 112.3, 110.2, 97.8, 69.8, 60.1, 35.5, 29.5, 24.2; HRMS 
(+ESI) Calcd. for C12H17N4O3 [M+H]+: 265.1301, found: 265.1309  
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Agelastatin B (2.2).  To a solution of agelastatin A 2.1 (1.9 mg, 5.6 !mol, 1.0 equiv) in 
2:1 THF:H2O (0.5 mL) was added 2,6-di-t-butyl-pyridine (1.9 !L, 8.4 !mol, 1.5 equiv) 
followed by N-bromosuccinimide (1.2 mg, 6.7!mol, 1.2 equiv) as a solid. After stirring 
for 1h, the reaction mixture was quenched by addition of a small crystal of sodium 
thiosulfate.  The mixture was concentrated to give a white residue. The residue was 
purified by preparative TLC eluting and washing with 10% MeOH in CH2Cl2 to give 2.1 
mg (90%) of agelastatin B 2.2 as a white solid: Rf = 0.19 (10% MeOH in DCM); IR (thin 
film): 3407, 1652, 1122 cm-1; 1H NMR (500 MHz; CD3OD): $ 6.97 (s, 1H), 4.60 (dt, J = 
12.0, 6.0 Hz, 1H), 4.11 (d, J = 5.5 Hz, 1H), 3.87 (m, 1H), 2.81 (s, 3H), 2.67 (dd, J = 
13.0, 6.5 Hz, 1H), 2.12 (app t, J = 13.0 Hz, 1H); 13C NMR (125 MHz; CD3OD): & 161.4, 
160.0, 124.8, 116.9, 108.7, 101.7, 95.6, 67.4, 62.0, 55.4, , 39.9, 24.22; HRMS (+ESI) 
Calcd. for C12H13Br2N4O3 [M+H]+: 420.9323, found: 420.9323  
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14-Iodo Agelastatin A (3.5).  To a solution of agelastatin A 2.1 (3.1 mg, 9.1 !mol, 1.0 
equiv) in 2:1 THF:H2O (1.0 mL) was added 2,6-di-t-butyl-pyridine (3.1 !L, 13.6 !mol, 
1.5 equiv) followed by N-iodosuccinimide (2.5 mg, 10.9 !mol, 1.2 equiv) as a solid, and 
In(OTf)3 (0.5 mg, 0.9 !mol, 0.1 equiv). After stirring for 1h, the reaction mixture was 
quenched by addition of a small crystal of sodium thiosulfate.  The mixture was 
concentrated to give a white residue. The residue was purified by preparative TLC 
eluting and washing with 10% MeOH in CH2Cl2 to give 4.2 mg (99%) of 3.5 as a white 
solid: Rf = 0.19 (10% MeOH in DCM); IR (thin film): 3290, 2916, 2848, 1697, 1655 cm-
1; 1H NMR (500 MHz; CD3OD): 7.03 (s, 1H), 4.62 (dt, J = 12.0, 6.0 Hz, 1H), 4.10 (d, J 
= 6.0 Hz, 1H), 3.87 (s, 1H), 2.81 (s, 3H), 2.67 (dd, J = 13.0, 6.5 Hz, 1H), 2.11 (app t, J = 
13.0 Hz, 1H); 13C NMR (125 MHz; CD3OD): & 161.4, 160.0, 126.2, 122.4, 113.7, 95.5, 
69.0, 67.4, 62.1, 55.9, 39.9, 24.2; HRMS (+ESI) Calcd. for C12H12BrIClN4O3 [M+Cl]+: 
500.8826, found: 500.8803  
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14-Alkynyl Agelastatin A (3.7).  A solution of 14-iodo agelastatin A 3.5 (5.0 mg, 10.7 
!mol, 1.0 equiv) in DMF/Et3N (0.75 mL) was degassed by bubbling argon for 15 
minutes.  Pd(PPh3)4 (3.7 mg, 3.2 !mol, 0.3 equiv) was then added followed by bis-
alkyne 3.6 (3.5 mg, 21.4 !mol, 2.0 equiv).  The reaction was sealed in argon, stirred at 
60 °C for 2h and concentrated in vacuo to give a yellow residue. The residue was 
purified by pipette flash column chromatography (SiO2, 10"15% MeOH/DCM) 
providing 2.3 mg (43%) of 14-alkynyl agelastatin A 3.7 as a thin film: Rf = 0.24 (10% 
MeOH in DCM); IR (thin film): 3275, 2848, 1700, 1650 cm-1; 1H NMR (500 MHz; 
CD3OD): $ 6.91 (s, 1H), 4.58 (dt, J = 12.0, 6.0 Hz, 1H), 4.09 (d, J = 5.5 Hz, 1H), 3.87 
(s, 1H), 2.81 (s, 3H), 2.67 (dd, J = 13.0, 6.5 Hz, 1H), 2.51 (t, J = 7.0 Hz, 2H), 2.40 (t, J = 
7.0 Hz, 2H), 2.12 (app t, J = 13.0 Hz, 1H), 1.76 (quintet, J = 7.0 Hz, 2H), 0.13 (s, 9H).; 
13C NMR (125 MHz; CD3OD): & 161.4, 160.5, 123.6, 117.6, 111.3, 110.6, 107.5, 95.6, 
92.5, 85.6, 74.1, 67.4, 62.0, 54.9, 39.9, 29.0, 24.2, 19.5, 19.1, 0.2; HRMS (+ESI) Calcd. 
for C22H28BrN4O3Si [M+H]+: 503.1114, found: 503.1135  
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13-Debromo Agelastatin A (3.8). To a solution of agelastatin A 2.1 (6.7 mg, 19.6 
!mol, 1.0 equiv) in 2:1 THF:H2O (2.0 mL) was added triethylamine (15 !L, 108 !mol, 
5.5 equiv) and 20 wt.% Pd(OH)2 on carbon (4.1 mg, 5.9 !mol, 0.3 equiv).  The reaction 
was purged with H2 stirred under this atmosphere for 6h. The reaction mixture was then 
filtered through a celite plug washing with 20% methanol in DCM.  The filtrate was 
concentrated in vacuo to give a white residue. The residue was purified by preparative 
TLC eluting and washing with 10% MeOH in CH2Cl2 to give 5.0 mg (97%) of 3.8 as a 
white solid: Rf = 0.12 (10% MeOH in DCM); IR (thin film): 3183, 2916, 1706, 1646 cm-
1; 1H NMR (500 MHz; CD3OD): $ 7.03 (dd, J = 2.5, 1.5 Hz, 1H), 6.89 (dd, J = 4.0, 1.5 
Hz, 1H), 6.24 (dd, J = 4.0, 2.5 Hz, 1H), 4.66 (dt, J = 10.0, 6.0 Hz, 1H), 4.00 (dd, J = 5.0, 
1.0 Hz, 1H), 3.81 (d, J = 1.0 Hz, 1H), 2.80 (s, 3H), 2.63 (dd, J = 13.0, 6.0 Hz, 1H), 2.28 
(dd, J = 13.0, 10.0 Hz, 1H); 13C NMR (125 MHz; CD3OD): & 162.1, 161.3, 125.6, 122.8, 
115.4, 111.1, 95.8, 68.0, 62.9, 55.6, 41.6, 24.2; HRMS (+ESI) Calcd. for C12H15N4O3 
[M+H]+: 263.1144, found: 263.1130 
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13-Alkynyl Agelastatin A (3.9).  A solution of agelastatin A 3.5 (3.1 mg, 9.1 !mol, 1.0 
equiv) in DMF/Et3N (1.0 mL) was degassed by bubbling argon for 15 minutes.  
Pd(PPh3)4 (6.4 mg, 5.5 !mol, 0.6 equiv) was then added followed by bis-alkyne 3.6 (4.5 
mg, 27.3 !mol, 3.0 equiv).  The reaction was sealed under argon, stirred at 60 °C for 6h 
and concentrated in vacuo to give a yellow residue. The residue was purified by pipette 
flash column chromatography (SiO2, 10"15% MeOH/DCM) providing 2.9 mg (75%) 
of 13-alkynyl agelastatin A 3.9 as a thin film: Rf = 0.22 (10% MeOH in DCM); IR (thin 
film): 3274, 2922, 1699, 1652 cm-1; 1H NMR (500 MHz; CD3OD): $ 6.83 (d, J = 4.0 
Hz, 1H), 6.37 (d, J = 4.0 Hz, 1H), 4.65 (dt, J = 12.0, 6.0 Hz, 1H), 4.07 (d, J = 5.5 Hz, 
1H), 3.87 (s, 1H), 2.82 (s, 3H), 2.63 (dd, J = 13.5, 7.0 Hz, 1H), 2.61 (t, J = 7.0 Hz, 2H), 
2.39 (t, J = 7.0 Hz, 2H), 2.13 (app t, J = 12.6 Hz, 1H), 1.79 (quintet, J = 7.0 Hz, 2H), 
0.13 (s, 9H).; 13C NMR (125 MHz; CD3OD): & 161.5, 161.3, 123.0, 119.9, 115.7, 114.8, 
107.1, 96.5, 95.7, 86.0, 71.8, 67.5, 62.4, 53.8, 40.3, 28.9, 24.4, 19.7, 19.1, 0.2 (3C); 
HRMS (+ESI) Calcd. for C22H28N4O3SiNa [M+Na]+: 447.1828, found: 447.1845 
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9-Methyl Agelastatin A (3.15). To a solution of agelastatin A 2.1 (2.0 mg, 5.9 !mol, 
1.0 equiv) in anhydrous DMF (0.5 mL) was added LiHMDS (6.4 !L of 1.0 M solution in 
THF, 6.4 !mol, 1.1 equiv).  After 30 min, TMSCl (5.9 !L of 1.0 M solution in THF, 5.9 
!mol, 1.0 equiv) was added to the reaction mixture.  After another 30 min of stirring, 
LiHMDS (6.4 !L of 1.0 M solution in THF, 6.4 !mol, 1.1 equiv) was added followed by 
MeI (11.7 !L of 0.5 M solution in THF, 5.9 !mol, 1.0 equiv) 30 minutes later.  The 
reaction mixture was stirred for another 30 min before addition TBAF (41 !L, 41.0 
!mol, 7.0 equiv). A 0.5 mL of saturated NH4Cl solution was added 30 minutes later. The 
reaction mixture was then filtered through a short silica gel plug washing with 20% 
methanol in DCM.  The filtrate was concentrated in vacuo to give a white residue. The 
residue was purified by preparative TLC eluting and washing with 10% MeOH in 
CH2Cl2 to give 1.5 mg (72%) of 3.15 as a white solid: Rf = 0.26 (10% MeOH in DCM); 
IR (thin film): 3248, 2925, 1691, 1632 cm-1; 1H NMR (500 MHz; CD3OD): $  6.89 (d, J 
= 4.0 Hz, 1H), 6.33 (d, J = 4.0 Hz, 1H), 4.70 (dt, J = 12.0, 6.0 Hz, 1H), 4.16 (s, 1H), 
4.02 (d, J = 6.0 Hz, 1H), 3.14 (s, 3H), 2.81 (s, 3H), 2.66 (dd, J = 13.0, 6.5 Hz, 1H), 2.10 
(dd, J = 13.0, 12.0 Hz, 1H); 13C NMR (125 MHz; CD3OD): &  124.3, 116.1, 114.1, 
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106.4, 94.8, 68.6, 66.0, 54.2, 41.0, 24.2 (carbonyls missing); HRMS (-ESI) Calcd. for 
C13H14BrN4O3 [M-H]-: 353.0249, found: 353.0233 
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14-Alkynyl biotin Agelastatin A (3.17). To a solution of 14-alkynyl agelastatin A 3.7 
(2.0 mg, 4.0 !mol, 1.0 equiv) in 2:1 THF:H2O (1.0 mL) was added TBAF (20 !L,  20 
!mol, 5.0 equiv) and stirred for 1 hour.   A CuSO4/sodium ascorbate stock solution 
(20!L, 1 !mol CuSO4, 10 !mol sodium ascorbate, 0.25 equiv CuSO4, 2.5 equiv sodium 
ascorbate) was then added.  (The stock solution was made from mixing equal volumes of 
0.1 M CuSO45H2O and 1.0 M sodium ascorbate aqueous solutions, until the initial black 
color turned light yellow.) After stirring for 24h, the reaction mixture was filtered 
through a cotton plug washing with 2:1 THF:water. The filtrate was concentrated in 
vacuo to give a yellow residue. The residue was purified by preparative TLC eluting and 
washing with 20% MeOH in DCM to give 1.3 mg (28%) of 3.17 as a thin film: Rf = 0.21 
(20% MeOH in DCM); 1H NMR (500 MHz; CD3OD): $ 7.86 (s, 1H), 6.92 (s, 1H), 
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4.61-4.56 (m, 1H), 4.55 (t, J = 5.0 Hz, 2H), 4.49 (dd, J = 8.0, 4.0 Hz, 1H), 4.30 (dd, J = 
8.0, 4.5 Hz, 1H), 4.10 (d, J = 5.5 Hz, 1H), 3.88 (s, 1H) 3.88 (t, J = 5.0 Hz, 2H), 3.69 (t, J 
= 6.0 Hz, 2H) 3.65-3.61 (m, 4H), 3.61-3.55 (m, 16H), 3.51 (td, J = 6.0, 3.0 Hz, 4H), 3.25 
(t, J = 7.0 Hz, 4H), 3.22-3.17 (m, 1H), 2.92 (dd, J = 13.0, 5.0 Hz, 1H), 2.90 (t, J =  8.0 
Hz, 2H), 2.81 (s, 3H), 2.69 (s, 1H), 2.70 (d, J = 13.0 Hz, 1H), 2.67 (dd, J = 12.0, 6.0 Hz, 
1H), 2.46 (t, J = 6.0 Hz, 2H), 2.41 (t, J = 6.0 Hz, 2H), 2.20 (t, J = 7.0 Hz, 2H), 2.11 (app 
t, J = 13.0 Hz, 2H), 2.03 (m, 1H), 2.07 (quintet, J = 7.5 Hz, 2H), 1.75 (app ddt, J = 13.0, 
6.5, 2.0 Hz, 4H), 1.55-1.71 (m, 4H), 1.43 (m, 2H); 13C NMR (125 MHz; CD3OD): & 
176.0, 173.9, 161.4, 160.4, 148.1, 124.3, 123.7, 117.6, 111.3, 110.6, 95.6, 92.9, 74.3, 
71.59, 71.54, 71.51, 71.47, 70.4,  69.98, 69.88, 68.3, 67.4, 63.4, 62.0, 61.6, 57.0, 54.9, 
51.4, 41.1, 39.9, 37.86, 37.83, 37.77, 36.9, 30.8, 30.4, 30.3, 29.8, 29.5, 26.9, 25.3, 24.3, 
19.5; HRMS (-ESI) Calcd. for C50H76BrN11O13K [M+K]+: 1188.4165, found: 1188.4216 
 
N
N
TrHO N
N
TrTBSO
4.7a 4.8  
 
Silyl ether (4.8): To a solution of alcohol 4.7a (3.0 g, 8.19 mmol) in 40 mL of DMF 
were added imidazole (5.58 g, 81.9 mmol) and TBSCl (1.60 g, 10.64 mmol) at 0 °C. The 
resulting solution was stirred for 30 min at 0 °C and allowed to warm to 25 °C for 
another 30 min, then it was diluted with 100 mL of Et2O and 100 mL of H2O. The 
organic phase was separated and the aqueous layer was extracted with 50 mL of Et2O 
twice. The combined organic layer was dried over MgSO4 and concentrated in vacuo to 
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leave a residue, which was purified by column chromatography on silica gel (gradient 
elution: 15:1'5:1 hexanes/EtOAc) to afford silyl ether 4.8 (3.09 g, 78%): IR (thin film): 
3059, 3029, 2955, 2931, 2854, 2360, 1495, 1445, 1247, 1111 cm-1; 1H NMR (500 MHz, 
CDCl3) " 0.08 (s, 6H), 0.91 (s, 9H), 4.31 (d, J = 3.5 Hz, 2H), 6.40 (dt, J = 16, 4.5 Hz, 
1H), 6.44 (d, J = 16 Hz, 1H), 6.74 (d, J = 1.5 Hz, 1H), 7.12–7.18 (m, 6H), 7.30–7.36 (m, 
9H), 7.39 (d, J = 1 Hz, 1H); 13C NMR (125 MHz, CDCl3) " –4.9, 18.8, 26.3, 64.0, 75.5, 
119.3, 121.4, 127.9, 128.4, 130.1, 139.3, 139.4, 142.6; HRMS (ESI): Calcd for 
C31H36N2OSi [M+H]: 481.2675. Found: 481.2670. 
 
N
N
TrTBSO N
N
TrTBSO
N3
4.8 4.8a  
 
Azidoimidazole (4.8a): To a solution of 4.8 (6.30 g, 13.11 mmol) in 200 mL of THF 
was added n-BuLi (2.50 M in hexane, 6.29 mL) dropwise at –78 °C. After being stirred 
at the same temperature for 1 h, TsN3 (3.88 mg, 19.67 mmol) in 20 mL of THF was 
added dropwise. The reaction was stirred for another 20 min at –78 °C, and diluted with 
400 mL of EtOAc and 400 mL of saturated NH4Cl. The organic layer was separated and 
the aqueous phase was extracted with 100 mL of EtOAc twice. The combined organic 
phase was dried over MgSO4 and concentrated in vacuo to leave a residual oil, which 
was purified by column chromatography on silica gel (gradient elution: 20:1'10:1 
hexanes/EtOAc) to furnish azidoimidazole 4.8a (6.43 g, 94%): IR (thin film): 2955, 
2366, 21334, 1495, 1418, 1250 cm-1; 1H NMR (500 MHz, CDCl3) " 0.09 (s, 6H), 0.93 
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(s, 9H), 4.31 (d, J = 3 Hz, 2H), 6.32–6.42 (m, 2H), 6.58 (s, 1H), 7.12–7.18 (m, 6H), 
7.29–7.36 (m, 9H); 13C NMR (125 MHz, CDCl3) " –4.9, 18.8, 26.3, 63.8, 75.3, 118.2, 
120.6, 128.0, 128.1, 128.2, 130.0, 136.2, 142.1, 142.6; HRMS (ESI): Calcd for 
C31H35N5OSi [M+H]: 522.2689. Found: 522.2610. 
 
N
N
TrTBSO N
N
TrHO
N3 N3
4.8a 4.9  
 
Alcohol (4.9): To a solution of 4.8a (30 mg, 0.058 mmol) in 1.0 mL of THF was added 
TBAF (1.0 M in THF, 0.17 mL) at 0°C. The resulting solution was stirred for 1 h and 
diluted with 5 mL of EtOAc and 5 mL of saturated NH4Cl. The organic phase was 
separated and the aqueous phase was extracted with 10 mL of EtOAc twice. The 
combined organic phase was dried over MgSO4 and concentrated in vacuo to leave a 
residual oil, which was purified by column chromatography on silica gel (gradient 
elution: 10:1'3:1 hexanes/EtOAc) to provide alcohol 14 (24 mg, quant.): IR (thin film): 
3062, 3032, 2925, 2360, 2132, 1489, 1415 cm-1; 1H NMR (500 MHz, CDCl3) " 1.90 (br 
s, 1H), 4.27 (d, J = 5.5 Hz, 2H), 6.37 (dt, J = 15.5, 1 Hz, 1H), 6.45 (dt, J = 15.5, 5,5 Hz, 
1H), 6.61 (s, 1H), 7.13–7.19 (m, 6H), 7.31–7.37 (m, 9H); 13C NMR (125 MHz, CDCl3) " 
63.7, 75.4, 118.7, 122.4, 127.6, 128.1, 128.2, 130.0, 135.7, 141.9, 142.8; HRMS (ESI): 
Calcd for C25H21N5O [M+Li]: 414.1906. Found: 414.1900. 
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Phthalimide (4.10): To a solution of alcohol 4.9 (1.25 g, 3.07 mmol) and LiCl (0.65 g, 
15.34 mmol) in 20 mL of THF were added Et3N (4.31 mL, 30.7 mmol) and MsCl (0.285 
mL, 3.68 mmol) dropwise sequentially at –50 °C. The resulting solution was stirred for 1 
h at the same temperature and diluted with 30 mL of EtOAc and 30 mL of saturated 
NaHCO3. The organic phase was separated and the aqueous phase was extracted with 30 
mL of EtOAc twice. The combined organic phase was dried over MgSO4 and 
concentrated in vacuo to provide a crude product, which was used for the next reaction 
without further purification. 
 
A solution of allylic chloride prepared above and 15N potassium phthalimide (572 mg, 
3.07 mmol) in 8.0 mL of DMF was stirred for 10 h at 25 °C. Then 20 mL of Et2O and 30 
mL of H2O were added to dilute the reaction mixture. The organic phase was separated 
and the aqueous layer was extracted with 20 mL of Et2O twice. The combined organic 
layer was dried over MgSO4 and concentrated in vacuo to leave a residue, which was 
purified by column chromatography on silica gel (gradient elution: 10:1'3:1 
hexanes/EtOAc) to furnish phthalimide 4.10 ( 692 mg, 42% from 4.9): IR (thin film): 
2363, 2342, 2132, 1712, 1489, 1418 cm-1; 1H NMR (500 MHz, CDCl3) " 4.39 (d, J = 6 
Hz, 2H), 6.29 (dt, J = 15.5, 5.5 Hz, 1H), 6.39 (d, J = 15.5 Hz, 1H), 6.57 (s, 1H), 7.08–
7.18 (m, 15H), 7.64–7.85 (m, 4H); 13C NMR (125 MHz, CDCl3) " 39.6 (d, JC-N = 95 
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Hz), 78.4, 119.2, 121.3, 123.9, 125.5(d, JC-N = 21 Hz), 128.1, 128.2, 129.9, 132.4 (d, JC-N 
= 75 Hz), 134.2, 134.6, 135.2, 141.9, 168.2 (d, JC-N = 133 Hz) ; HRMS (ESI): Calcd for 
C33H24N515NO2 [M+Li]: 544.2091. Found: 544.2131. 
 
N
H
Br
Br
H
N
O
N
N
N3
Tr15N N
N
N3O
O
15
Tr
4.10 4.11  
 
Pyrrole-2-carboxylate ester (4.11): To a solution of 4.10 (30 mg, 0.056 mmol) in 2.0 
mL of EtOH was added NH2NH2 (0.035 mL, 1.12 mmol). The resulting solution was 
stirred for 2 h at 50 °C during which time a white precipitate appeared. The reaction 
mixture was cooled to 25 °C and diluted with 10 mL CH2Cl2. The mixture was filtered 
with CH2Cl2 through a pad of Celite. The filtrate was concentrated in vacuo to obtain  
crude amine 4.10a, which was used for the next reaction without further purification. 
To a solution of crude allyl amine 4.10a prepared above in 0.5 mL of DMF were added 
Na2CO3 (30 mg, 0.28 mmol) and 4,5-dibromo-2-trichloroacetylpyrrole (62 mg, 0.17 
mmol). The resulting mixture was stirred for 6 h at 25 °C and diluted with 20 mL of 
Et2O and 30 mL of H2O. The organic phase was separated and the aqueous layer was 
extracted with 20 mL of Et2O twice. The combined organic layer was dried over MgSO4 
and concentrated in vacuo to leave a residue, which was purified by column 
chromatography on silica gel (gradient elution: 10:1'3:1 hexanes/EtOAc) to obtain 
4.11 (29 mg, 78% from 4.10): IR (thin film) 2339, 2132, 1632, 1429, 1421 cm-1; 1
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NMR (500 MHz, CDCl3) " 4.16 (s, 2H), 6.32 (S, 1H), 6.52 (s, 1H), 6.58 (s, 1H), 7.10–
7.18 (m, 6H), 7.28–7.38 (m, 9H), 11.0 (br s, 1H); 13C NMR (125 MHz, CDCl3) " 41.7 
(d, JC-N = 106 Hz), 75.5, 99.9, 106.2, 112.2, 119.0, 123.5, 124.3 (d, JC-N = 15 Hz), 128.2, 
128.3, 129.9, 135.3, 141.9. 143.1, 159.6 (d, JC-N = 175 Hz); HRMS (ESI): Calcd for 
C30H23N615NO [M+Li]: 665.0441. Found: 665.0499. 
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4.11a  
 
15N-azido-oroidin (4.11a): To a solution of 4.11 (380 mg, 0.58 mmol) in 20 mL of 
EtOAc was added HCl, which was prepared by addition of AcCl (2.06 mL, 28.9 mmol) 
to MeOH (1.17 mL, 28.9 mmol) dropwise at 0 °C. The solution was stirred for 1.5 h at 
25 °C and during that time there was some precipitate formed. The reaction mixture was 
filtered to separate the solid product of azidoimidazole hydrochloride salt (240 mg, 
quant.), which was of sufficient pure for the next reaction: IR (thin film) 3115, 233, 
2150, 1611, 1555, 1439 cm-1; 1H NMR (500 MHz, CD3OD) " 4.11 (d, J = 5 Hz, 2H), 
6.35 (dt, J = 16, 3.5 Hz, 1H), 6.43 (d, J = 16 Hz, 1H), 6.89 (d, J = 2 Hz, 1H), 7.31 (s, 
1H); 13C NMR (125 MHz, CD3OD) " 42.3 (d, JC-N = 114 Hz), 100.8, 107.3, 115.2, 
116.3, 117.5 (d, JC-N = 22.5 Hz), 129.4 (d, JC-N = 106 Hz), 131.8, 132.3, 142.6, 162.4 (d, 
JC-N = 174 Hz); HRMS (ESI): Calcd for C11H9Br2N615NO [M+H]: 416.9163. Found: 
416.9171. 
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15N-oroidin (1.1b): To a solution of azidoimidazole hydrochloride salt 4.11a (210 mg, 
0.50 mmol) in 30 mL of MeOH/EtOAc (1 : 1) was added Lindlar catalyst (100 mg, 5% 
Pd on CaCO3, poisioned with Pb). The resulting mixture was stirred under atmospheric 
hydrogen at 25 °C for 6 h then filtered with MeOH through a pad of Celite. The filtrate 
was concentrated in vacuo to leave a residue, which was purified on column 
chromatography on silica gel (gradient elution: 10:1:0'1:1:0.01 
CH2Cl2/MeOH/NH4OH) to furnish 15N-oroidin 1.1b (165 mg, 84%): IR (thin film): 
3304, 2363, 2339, 1620, 1507, 1415 cm-1; 1H NMR (500 MHz, CD3OD) " 4.00 (d, J = 6 
Hz, 2H), 5.87 (dt, J = 16, 6 Hz, 1H), 6.30 (d, J = 16 Hz, 1 H), 6.47 (s, 1H), 6.83 (d, J = 1 
Hz, 1H); 13C NMR (125 MHz, CD3OD) " 43.1 (d, JC-N = 106 Hz), 100.7, 107.0, 115.1, 
118.5, 122.2, 123.6 (d, JC-N = 15 Hz), 129.7 (d, JC-N = 99 Hz), 132.2, 152.8,  162.4 (d, JC-
N = 175 Hz); 15N NMR (CD3SOCD3) " –272.8 (relative to MeNO2); HRMS (ESI): Calcd 
for C11H11Br2N415NO [M+H]: 390.9258. Found: 390.9289. 
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N-Methyl Propargyl phthalimide (4.13).  To a solution of 4.18 (970 mg, 2.47 mmol, 
1.0 equiv) in DCM was added BF4OMe3 (404 mg, 2.60 mmol, 1.05 equiv) in a glove 
box.  The reaction mixture was stired for 3.5 h followed by addition of 15mL of 
methanol.  After 30 min, the mixture was concentrated in vacuo to give a yellow residue. 
The residue was purified by flash column chromatography (SiO2, 30"50% 
EtOAc/Hexanes) to deliver 343.6 mg (52%) of adduct 4.13 as off-white solids: 1H NMR 
(500 MHz; CDCl3): & 7.89 (dd, J = 5.5, 3.0 Hz, 2H), 7.75 (dd, J = 5.5, 3.0 Hz, 2H), 7.40 
(s, 1H), 7.23 (s, 1H), 4.71 (d, J = 1.0 Hz, 2H), 3.65 (s, 3H).; 13C NMR (125 MHz; 
CD3OD): & 167.2 (d, JC-N = 12.5 Hz), 138.5, 135.1, 134.4, 132.1 (d, JC-N = 8.1 Hz),, 
123.8, 115.4, 90.3, 71.6, 32.2, 28.1 (d, JC-N = 11.6 Hz)  
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Table S1. Comparison of 1H NMR data of natural and synthetic  
agelastatin A in CD3OD. 
 
 
Assignment natural3 (300 MHz) 
& (ppm) (multiplicity, J in Hz, #H) 
synthetic (500 MHz, this work)   
& (ppm) (multiplicity, J in Hz, #H) 
C15-H! 6.92 (br d, J = 4.2 Hz, 1H )! 6.91 (d, J = 4.0 Hz, 1H )!
C14-H! 6.33 (d, J = 4.2 Hz, 1H)! 6.33 (d, J = 4.0 Hz, 1H)!
C7-H! 4.60 (m, J = 12.3, 6.6, 5.4 Hz, 1H)! 4.60 (app dt, J = 12.0, 6.0 Hz, 1H)!
C8-H! 4.09 (br d, J = 5.4 Hz, 1H)! 4.09 (d, J = 5.5 Hz, 1H)!
C4-H! 3.89 (br s, 1H)! 3.88 (s, 1H)!
N1-Me! 2.81 (s, 3H)! 2.81 (s, 3H)!
C6-H(! 2.65 (br dd, J = 12.9, 6.6 Hz, 1H)! 2.65 (dd, J = 13.0, 6.5 Hz, 1H)!
C6-H%! 2.10 (br t, J = 12.9 Hz, 1H)! 2.10 (app t, J = 13.0 Hz, 1H)!
 
 
 
 
 
 
                                                
3 D'Ambrosio, A. Guerriero, C. Debitus, O. Ribes, J. Pusset, S. Leroy, F. Pietra, J. Chem. Soc., 
Chem. Commun. 1993, 16, 1305-1306. 
   
 141 
NH
N
N
NH
O
O
Br
HO
H
Me
4
1
36
8
5
910
12
13
14
15
11
7
2
agelastatin A (2.1)  
 
Table S2. Comparison of 13C NMR data of natural and synthetic  
agelastatin A in CD3OD. 
 
 natural3  
(& in ppm,  
75MHz) 
(d) 
synthetic 
(Hale)4  
(& in ppm,  
125 MHz) 
 (&) 
synthetic  
(Du Bois)5  
(& in ppm,  
125 MHz) 
 
synthetic  
(this work) 
(& in ppm, 1 
25 MHz) 
 (&) 
C2 163.00! 161.4 
 
 
 
 
 
 
 
 
!
161.4 
 
 
 
 
 
 
 
 
!
161.4 
 
 
 
 
 
 
 
 
!
C10 162.65! 161.1! 161.1! 161.1!
C11 125.71! 124.1! 124.1! 124.1!
C15 117.59! 116.0! 116.0! 116.0!
C14 115.37! 113.8! 113.8! 113.8!
C13 108.80! 107.2! 107.3! 107.3!
C5 97.24! 95.6! 95.6! 95.7!
C4 68.98! 67.4 67.4 67.4 
C8 63.76! 62.2! 62.2! 62.2!
C7 55.96! 54.3! 54.4! 54.4!
C6 41.58! 40.0! 40.0! 40.0!
N1-Me 25.79! 24.2! 24.2 24.2!
  
 
 
                                                
4 M. M. Domostoj, E. Irving, F. Scheinmann, K. J. Hale, Org. Lett. 2004, 6, 2615-2618. 
5 P. M. Wehn, B. J. Du Bois, Angew. Chem., Int. Ed. 2009, 48, 3802-3805 
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Table S3. Comparison of 1H NMR data of 4,5-bis-epi-agelastatin A in CD3OD. 
 
Assignment Pietra’s report6 (300 MHz) 
& (ppm) (multiplicity, J in Hz, #H) 
this work (500 MHz)   
& (ppm) (multiplicity, J in Hz, #H) 
C15-H! 6.90 (d, J = 4.2 Hz, 1H )! 6.90 (d, J = 4.0 Hz, 1H)!
C14-H! 6.33 (d, J = 4.2 Hz, 1H)! 6.33 (d, J = 4.0 Hz, 1H)!
C7-H! 5.00 (ddd, J = 10.5, 6.9, 5.4 Hz, 1H)! 5.00 (ddd, J = 10.5, 7.0, 5.0 Hz, 1H)!
C8-H! 4.43 (t, J = 5.4 Hz, 1H)! 4.42 (app t, J = 5.5 Hz, 1H),!
C4-H! 4.02 (d, J = 5.4 Hz, 1H)! 4.01 (d, J = 6.0 Hz, 1H)!
N1-Me! 2.73 (s, 3H)! 2.73 (s, 3H)!
C6-H’! 2.53 (dd, J = 13.2, 6.9 Hz, 1H)! 2.52 (dd, J = 13.0, 7.0 Hz, 1H)!
C6-H’’! 2.26 (dd, J = 13.2, 10.5 Hz, 1H)! 2.26 (dd, J = 13.0, 10.5 Hz, 1H)!
 
 
 
 
 
 
 
 
                                                
6 M. D'Ambrosio, A. Guerriero, M. Ripamonti, C. Debitus, J. Waikedre, F. Pietra, Helv. 
Chim. Acta 1996, 79, 727-735. 
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Figure S1. Single crystal X-ray structure (ORTEP) of cyclization precursor 2.84 
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Crystal data and structure refinement for 2.84. 
 
Identification code  drbm 
Empirical formula  C22 H25 Br N4 O6 S 
Formula weight  553.43 
Temperature  110(2) K 
Wavelength  1.54178 Å 
Crystal system  Monoclinic 
Space group  P2(1)/n 
Unit cell dimensions a = 14.4647(7) Å a= 90°. 
 b = 11.6582(5) Å b= 104.740(4)°. 
 c = 14.8181(7) Å g = 90°. 
Volume 2416.58(19) Å3 
Z 4 
Density (calculated) 1.521 Mg/m3 
Absorption coefficient 3.522 mm-1 
F(000) 1136 
Crystal size 0.40 x 0.12 x 0.08 mm3 
Theta range for data collection 3.81 to 60.00°. 
Index ranges -15<=h<=15, -11<=k<=12, -15<=l<=16 
Reflections collected 33741 
Independent reflections 3444 [R(int) = 0.0798] 
Completeness to theta = 60.00° 96.4 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7659 and 0.3331 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3444 / 17 / 338 
Goodness-of-fit on F2 1.073 
Final R indices [I>2sigma(I)] R1 = 0.0708, wR2 = 0.2153 
R indices (all data) R1 = 0.0932, wR2 = 0.2605 
Extinction coefficient 0.0029(5) 
Largest diff. peak and hole 0.860 and -1.350 e.Å-3 
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Figure S2. Single crystal X-ray structure (ORTEP) of DMB aldehyde 2.58b 
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Crystal data and structure refinement for 2.58b 
 
Identification code  drb1005 
Empirical formula  C14 H16 N2 O4 
Formula weight  276.29 
Temperature  110(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 11.146(3) Å a= 90°. 
 b = 15.768(5) Å b= 108.066(4)°. 
 c = 8.036(2) Å g = 90°. 
Volume 1342.7(7) Å3 
Z 4 
Density (calculated) 1.367 Mg/m3 
Absorption coefficient 0.101 mm-1 
F(000) 584 
Crystal size 0.40 x 0.30 x 0.06 mm3 
Theta range for data collection 1.92 to 27.51°. 
Index ranges -14<=h<=14, -20<=k<=20, -10<=l<=10 
Reflections collected 15135 
Independent reflections 3075 [R(int) = 0.0435] 
Completeness to theta = 27.51° 99.4 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9939 and 0.9606 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3075 / 0 / 181 
Goodness-of-fit on F2 1.026 
Final R indices [I>2sigma(I)] R1 = 0.0402, wR2 = 0.0978 
R indices (all data) R1 = 0.0579, wR2 = 0.1104 
Largest diff. peak and hole 0.270 and -0.226 e.Å-3 
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TD-DFT Calculations of N-acyliminium 2.87 
Herein, we aim to provide rationalization of the observed deep red color during the first 
cyclization event (2.84"2.88), which we propose to be due to the formation of N-
acyliminium 2.87, the most likely intermediate formed in solution prior to nucleophilic 
quenching.  To this end, we obtained a UV-VIS spectrum of the reaction mixture as 
illustrated in figure S3.  Four absorption bands were identified and for the most part we 
are interested in band 4, which confirms absorption in the blue-green region of the 
visible spectrum and accounts for the red color observed.   
 
Figure S3. UV-Vis spectrum of the reaction (2.84"2.88) in CH2Cl2. 
 
 
 
 
 
 
 
 
 
 
 
 
Band 1
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Table S4.  Absorbance maxima of tosyl and pyrrole moieties in dichloromethane. 
 
Absorbance maxima (nm)  Compound 
Experimental B3LYP/6-31+G(d)  
1 Ts OMs  229 224 
2 
NH
O
NHOMe
Br
 
261 261 
3 
NH
O
NH2
Br
 
273 273 
 
 
We then turned to Time-Dependent Density Functional Theory (TD-DFT) to predict the 
excited states of the proposed intermediate 2.87.  TD-DFT is the most widely used ab 
initio tool for modeling vertical excitations.  At the outset, we sought to identify 
absorption bands due to the aromatic pyrrole and tosyl moieties of 2.87 and assess the 
utility of TD-DFT.  For this purpose, calculations were performed on simpler sub-
structures listed in table S4 and the results show remarkable agreement of experimental 
and calculated absorption maxima. These results allowed us to assign bands 1 and 2 as 
the corresponding tosyl-ethyl and bromopyrrole amide moieties, respectively, of 
intermediate 2.87.    
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As anticipated, TD-DFT-predicted electronic spectra of proposed intermediate 2.87 also 
showed four absorption bands that were in good agreement the experimental results (see 
Table S5).  This provides further verification of 2.87 as the intermediate formed in 
solution during the first cyclization.  Figure S4 shows the comparative estimation of the 
accuracy of the calculated results versus the experimental values. Since the quality of 
obtained results is highly functional dependent, several functionals were screened.  
B3LYP and X3LYP hybrid functionals gave the best fit while larger basis sets provided 
minimal variation.  While band 3 was least accurately predicted, it is still within error 
observed in TD-DFT calculations of other organic systems. Larger deviations are usually 
observed with charged species. 7 
 
Table S5. Experimental versus TD-DFT predicted absorption bands. 
*6-31+G(d) (solvent=dichloromethane) 
                                                
7 D. Jacquemin, E. A. Perpete, G. E. Scuseria, I. Ciofoni, C. Adamo, J. Chem. Theory Comput. 
2008, 4, 123-135.; D. Jacquemin, V. Wathelet, E. A. Perpete, C. Adamo, J. Chem. Theory 
Comput. 2009, 5, 2420-2435. 
 
Absorption maxima (nm) 
 Band 1 Band 2 Band 3 Band 4 
experimental 230 274 383 509 
B3LYP* 226 281 340 527 
X3LYP* 225 280 332 509 
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Figure S4. Experimental versus TD-DFT predicted absorption bands. 
 
Visualized in table S6 are the orbital pairs involved in each excited state.  These orbital 
portraits, respectively, further confirm the initial assignment of bands 1 and 2 as the 
tosyl-ethyl and bromopyrrole amide moieties.  Band 3 is shown to be a !"!* transition 
involving ! orbitals of the amide bond to the !* orbitals of the acyliminium moiety.  
Most importantly, band 4, which is responsible for the red color of intermediate 2.87, is 
revealed to be a !"!* transition between the HOMO (composed mostly of orbital 
contributions from the bromopyrrole amide moiety) and the LUMO (composed mostly 
of orbital contributions from the acyliminium moiety). 
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Table S6. Orbital pairs involved in each transition. 
 
 Occupied MO* Unoccupied MO* 
Band 1  
(230 nm) 
 
 
 
 
 
Band 2  
(274 nm) 
 
 
 
 
 
 
Band 3  
(383 nm) 
 
 
 
 
 
*isovalue for surface = 0.04 
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Table S6. Continued. 
 
 Occupied MO* Unoccupied MO* 
Band 4  
(509 nm) 
 
 
 
 
 
*isovalue for surface = 0.04 
 
 
Computational Methods 
All structures were optimized in the gas phase. For geometry and frequency 
optimizations, the B3LYP level of theory with the 6-31+G(d) basis set was employed 
and no symmetry constraints were imposed.  Time-Dependent Density Functional 
Theory (TD-DFT) single point calculations were performed on the optimized structures 
to obtain calculated absorption bands.  Solvation was performed using the scrf keyword 
which defaults to a Polarizable Continuum Model (PCM) of solvation.  Dichloromethane 
was employed as solvent to closely mimic our experimental results.  All calculations 
were done within the Gaussian 09 program. 
 
The following input files gave the corresponding output below for the excitations within 
the TD-DFT method. 
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Ts OMs  
 
Input File: 
 
%chk=g09.chk     
#p td scrf=(solvent=dichloromethane) b3lyp/6-31+G(d) pop=full gfinput 
 
TSeOMs 
 
0 1 
 C    -8.958866    -2.719394     1.390920 
 C    -7.459873    -2.730552     1.204949 
 C    -6.773233    -1.564602     0.831297 
 C    -5.393169    -1.572841     0.627251 
 C    -4.689851    -2.766440     0.804783 
 S    -2.910203    -2.789214     0.559938 
 C    -2.234929    -2.439050     2.223311 
 C    -0.706960    -2.495916     2.181412 
 O    -0.136960    -1.934967     3.394859 
 S    -0.170957    -2.870394     4.755401 
 C     1.197378    -2.072719     5.600351 
 O     0.182065    -4.243714     4.390586 
 O    -1.412993    -2.610559     5.484296 
 O    -2.544536    -1.648184    -0.302243 
 O    -2.505412    -4.162434     0.204370 
 C    -5.345674    -3.944503     1.171073 
 C    -6.725569    -3.915702     1.371259 
 H    -9.469539    -2.968932     0.451046 
 H    -9.316993    -1.733704     1.706178 
 H    -9.275283    -3.453675     2.139332 
 H    -7.325943    -0.638372     0.691909 
 H    -4.868628    -0.673721     0.318710 
 H    -2.656634    -3.178957     2.908628 
 H    -2.581475    -1.440532     2.503370 
 H    -0.342992    -3.516313     2.042128 
 H    -0.312208    -1.854689     1.391539 
 H     1.273950    -2.550126     6.580013 
 H     2.106305    -2.228618     5.017977 
 H     0.966868    -1.011464     5.706471 
 H    -4.785197    -4.867899     1.281167 
 H    -7.240769    -4.830295     1.655580 
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NHOMe
Br
 
 
Input File: 
 
%chk=g09.chk     
#p td scrf=(solvent=dichloromethane) b3lyp/6-31+G(d) pop=full gfinput 
 
BrPyCONHOMe 
 
0 1 
 O     5.139733    -0.809091     0.661133 
 C     4.066531    -0.311128     0.331798 
 N     2.918015    -1.063406     0.117706 
 O     2.875902    -2.320402     0.733719 
 C     3.289795    -3.342566    -0.184046 
 C     3.939850     1.126779     0.051265 
 C     2.911856     1.973410    -0.352821 
 C     3.440908     3.284626    -0.438214 
 C     4.777024     3.192850    -0.084530 
Br     6.077257     4.536525     0.022353 
 N     5.071460     1.898990     0.205971 
 H     2.024437    -0.601311     0.251393 
 H     3.186327    -4.274602     0.377009 
 H     4.333424    -3.196027    -0.477585 
 H     2.639053    -3.357137    -1.066429 
 H     1.892726     1.687737    -0.579090 
 H     2.922089     4.188460    -0.723933 
 H     5.962592     1.517063     0.498290 
 
NH
O
NH2
Br
 
 
Input File: 
 
%chk=g09.chk     
#p td scrf=(solvent=dichloromethane) b3lyp/6-31+G(d) pop=full gfinput 
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BrPyCOONH2 
 
0 1 
 O     4.899949    -0.414208    -0.546125 
 C     3.843533     0.219236    -0.463968 
 N     2.631482    -0.347352    -0.737374 
 C     3.847464     1.635680    -0.063344 
 C     2.878392     2.615620     0.122533 
 C     3.537474     3.805430     0.520649 
 C     4.889643     3.508632     0.563712 
Br     6.338182     4.609348     1.010580 
 N     5.069625     2.208495     0.213475 
 H     1.760095     0.155425    -0.661032 
 H     2.610247    -1.321359    -1.005370 
 H     1.810267     2.500600    -0.010852 
 H     3.091558     4.762828     0.749446 
 H     5.940980     1.696255     0.148960 
 
N
N
NH
NH
O
H
O
Br Ts
Me
2.87
 
 
Input File: 
 
%chk=g09.chk     
#p td=(NStates=30) scrf=(solvent=dichloromethane) b3lyp/6-31+G(d) pop=full gfinput  
 
intermediate 2   
 
1 1 
 O     4.353444     2.515132    -1.202826 
 C     4.172115     1.515455    -0.559751 
 N     3.097102     0.677426    -0.471155 
 C     1.829939     0.950722    -1.169271 
 C     0.838172     1.757537    -0.315329 
 S    -0.823715     1.638830    -1.093824 
 C    -1.846142     2.779398    -0.171366 
 C    -1.944881     4.106303    -0.604600 
 C    -2.748407     4.989498     0.113176 
 C    -3.456663     4.570140     1.252932 
  156 
 C    -4.314195     5.544488     2.023071 
 C    -3.343542     3.229924     1.654792 
 C    -2.544795     2.327678     0.951508 
 O    -1.294616     0.262088    -0.826357 
 O    -0.668485     2.125634    -2.473774 
 C     3.303437    -0.326514     0.549246 
 H     2.690753    -0.113086     1.438531 
 C     4.749739    -0.165913     0.864433 
 C     5.299802    -1.364003     1.424898 
 C     4.426159    -2.364397     1.121401 
 C     3.218684    -1.909423     0.339063 
 H     3.359507    -2.105191    -0.733076 
 N     2.003739    -2.554083     0.728062 
 C     0.941439    -2.568476    -0.188311 
 C    -0.338786    -3.033647     0.299496 
 C    -0.735278    -3.785558     1.409502 
 C    -2.134628    -3.933442     1.344543 
 C    -2.552801    -3.254316     0.204002 
Br    -4.277295    -3.055987    -0.478023 
 N    -1.474431    -2.735646    -0.428932 
 O     1.131983    -2.163605    -1.337788 
 N     5.225557     0.917829     0.312006 
 C     6.604388     1.414725     0.277289 
 H     1.409913    -0.015542    -1.457766 
 H     2.080082     1.500926    -2.077740 
 H     1.108325     2.816013    -0.260917 
 H     0.725144     1.355311     0.696272 
 H    -1.425498     4.429803    -1.501471 
 H    -2.839573     6.018534    -0.225899 
 H    -4.938554     6.142407     1.349916 
 H    -4.971622     5.030611     2.730695 
 H    -3.691203     6.245072     2.594252 
 H    -3.900622     2.881878     2.520926 
 H    -2.489626     1.285334     1.249703 
 H     6.272981    -1.470265     1.888733 
 H     4.574020    -3.412425     1.368102 
 H     1.783828    -2.630689     1.714444 
 H    -0.084216    -4.232976     2.150194 
 H    -2.772949    -4.482136     2.021904 
 H    -1.491303    -2.072412    -1.197690 
 H     6.578141     2.404270    -0.181076 
 H     7.225903     0.747976    -0.328124 
 H     6.996415     1.481087     1.29385
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1H NMR (500 MHz) of 2.47 in DMSO-d6 
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13C NMR (125 MHz) of 2.47 in DMSO-d6 
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1H NMR (500 MHz) of 2.58 in CDCl3 
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13C NMR (125 MHz) of 2.58 in CDCl3 
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1H NMR (500 MHz) of 2.58a in CDCl3 
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13C NMR (125 MHz) of 2.58a in CDCl3 
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1H NMR (500 MHz) of 2.59 in CDCl3 
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13C NMR (125 MHz) of 2.59 in CDCl3 
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1H NMR (500 MHz) of 2.82 in acetone-d6 
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13C NMR (125 MHz) of 2.82 in acetone-d6 
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1H NMR (500 MHz) of 2.83 in CD3OD 
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13C NMR (125 MHz) of 2.83 in CD3OD 
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1H NMR (500 MHz) of 2.84 in CDCl3/CD3OD (1:1) 
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13C NMR (125 MHz) of 2.84 in CDCl3/CD3OD (1:1) 
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1H NMR (500 MHz) of 2.88 in CD3OD 
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13C NMR (125 MHz) of 2.88 in CD3OD 
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1H NMR (500 MHz) of 2.89 in CD3OD 
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13C NMR (125 MHz) of 2.89 in CD3OD 
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1H NMR (500 MHz) of 2.1 in CD3OD 
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13C NMR (125 MHz) of 2.1 in CD3OD 
 
  177 
 
 
 
1H NMR (500 MHz) of 2.102 in CD3OD 
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13C NMR (125 MHz) of 2.102 in CD3OD 
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1H NMR (500 MHz) of 3.3 in CD3OD 
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13C NMR (125 MHz) of 3.3 in CD3OD 
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1H NMR (500 MHz) of 2.2 in CD3OD 
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13C NMR (125 MHz) of 2.2 in CD3OD 
 
  183 
 
 
 
 
1H NMR (500 MHz) of 3.5 in CD3OD 
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13C NMR (125 MHz) of 3.5 in CD3OD 
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1H NMR (500 MHz) of 3.7 in CD3OD 
  186 
 
 
 
 
13C NMR (125 MHz) of 3.7 in CD3OD 
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1H NMR (500 MHz) of 3.8 in CD3OD 
  188 
 
 
 
 
13C NMR (125 MHz) of 3.8 in CD3OD 
  189 
 
 
 
 
1H NMR (500 MHz) of 3.9 in CD3OD 
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13C NMR (125 MHz) of 3.9 in CD3OD 
  191 
 
 
 
 
1H NMR (500 MHz) of 3.15 in CD3OD 
  192 
 
 
 
 
13C NMR (125 MHz) of 3.15 in CD3OD 
  193 
 
 
 
 
1H NMR (500 MHz) of 3.17 in CD3OD 
 
  194 
 
 
 
13C NMR (125 MHz) of 3.17 in CD3OD 
 
  195 
 
 
1H NMR (500 MHz) of 4.8 in CDCl3 
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13C NMR (125 MHz) of 4.8 in CDCl3 
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1H NMR (500 MHz) of 4.8a in CDCl3 
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13C NMR (125 MHz) of 4.8a in CDCl3 
 
 
  199 
 
 
1H NMR (500 MHz) of 4.9 in CDCl3 
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13C NMR (125 MHz) of 4.9 in CDCl3 
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1H NMR (500 MHz) of 4.10 in CDCl3 
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13C NMR (125 MHz) of 4.10 in CDCl3 
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1H NMR (500 MHz) of 4.11 in CDCl3 
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13C NMR (125 MHz) of 4.11 in CDCl3 
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1H NMR (500 MHz) of 4.11a in CD3OD 
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13C NMR (125 MHz) of 4.11a in CD3OD 
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1H NMR (500 MHz) of 1.1b in CD3OD 
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13C NMR (125 MHz) of 1.1b in CD3OD 
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1H NMR (500 MHz) of 4.18 in CDCl3 
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1H NMR (500 MHz) of 4.13 in CDCl3 
 
 
  211 
 
 
 
13C NMR (125 MHz) of 4.13 in CDCl3 
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APPENDIX B 
LETTERS OF PERMISSION 
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